F1_R2

C Number:	C20005
Lock Date:	09/07/2006
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	2.0.0

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Ginseng

MALE RATS

Organ	Morphology
Eye: Retina	Degeneration
Heart: Atrium	Thrombosis
Intestine Large, Colon	Parasite Metazoan
Kidney	Mineralization
	Nephropathy
Liver	Fatty Change Diffuse
	Fatty Change Focal
	Necrosis
Liver: Bile Duct	Hyperplasia
Lung	Thrombosis
Lymph Node: Mediastinal	Ectasia
Nose: Olfactory Epithelium	Inflammation
Skin: Epidermis	Cyst Epithelial Inclusion
	Hyperplasia
Stomach, Forestomach	Inflammation
	Necrosis
Stomach, Forestomach: Epithelium	Hyperplasia

FEMALE RATS

Organ	Morphology
Bone: Femur	Osteopetrosis
Eye: Cornea	Fibrosis
Kidney	Mineralization
Kidney: Pelvis	Inflammation
Liver	Basophilic Focus
Liver: Bile Duct	Hyperplasia
Lymph Node, Mesenteric	Hyperplasia Lymphoid
Nose: Olfactory Epithelium	Inflammation
Nose: Respiratory Epithelium	Inflammation

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Adrenal Cortex
Degeneration Cystic

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/42.38	0/43.21	1/45.92	1/39.67
POLY-3 PERCENT (g)	2.4%	0%	2.2%	2.5%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	727 (T)	---	652	716

STATISTICAL TESTS

POLY 3	P=0.515	P=0.496N	P=0.743N	P=0.746
POLY 1.5	P=0.521	P=0.497N	P=0.752N	P=0.750
POLY 6	P=0.507	P=0.495N	P=0.732N	P=0.741
COCH-ARM / FISHERS	P=0.539	P=0.500N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.525	P=0.158N	P=0.477N	P=0.481

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Adrenal Cortex Hypertrophy				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	4/50 (8%)	4/50 (8%)
POLY-3 RATE (b)	1/42.38	2/43.56	4/45.92	4/40.77
POLY-3 PERCENT (g)	2.4%	4.6%	8.7%	9.8%
TERMINAL (d)	1/30 (3%)	1/30 (3%)	3/37 (8%)	2/23 (9%)
FIRST INCIDENCE	727 (T)	629	652	259
STATISTICAL TESTS				
POLY 3	P=0.100	P=0.510	P=0.204	P=0.166
POLY 1.5	P=0.104	P=0.506	P=0.191	P=0.169
POLY 6	P=0.095	P=0.513	P=0.219	P=0.160
COCH-ARM / FISHERS	P=0.114	P=0.500	P=0.181	P=0.181
MAX-ISO-POLY-3	P=0.143	P=0.291	P=0.107	P=0.080

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Adrenal Cortex **Necrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.38	1/43.51	0/45.64	2/40.58
POLY-3 PERCENT (g)	0%	2.3%	0%	4.9%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	1/23 (4%)
FIRST INCIDENCE	---	645	---	259
STATISTICAL TESTS				
POLY 3	P=0.135	P=0.505	(e)	P=0.227
POLY 1.5	P=0.136	P=0.503	(e)	P=0.230
POLY 6	P=0.134	P=0.507	(e)	P=0.222
COCH-ARM / FISHERS	P=0.140	P=0.500	(e)	P=0.247
MAX-ISO-POLY-3	P=0.077	P=0.165	(e)	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Adrenal Cortex: Zona Fasciculata
Hyperplasia

LESION RATES

OVERALL (a)	9/50 (18%)	6/50 (12%)	7/50 (14%)	6/50 (12%)
POLY-3 RATE (b)	9/42.73	6/43.21	7/45.64	6/40.55
POLY-3 PERCENT (g)	21.1%	13.9%	15.3%	14.8%
TERMINAL (d)	7/30 (23%)	6/30 (20%)	7/37 (19%)	3/23 (13%)
FIRST INCIDENCE	652	727 (T)	727 (T)	617

STATISTICAL TESTS

POLY 3	P=0.320N	P=0.276N	P=0.337N	P=0.323N
POLY 1.5	P=0.318N	P=0.279N	P=0.364N	P=0.317N
POLY 6	P=0.321N	P=0.278N	P=0.308N	P=0.332N
COCH-ARM / FISHERS	P=0.291N	P=0.288N	P=0.393N	P=0.288N
MAX-ISO-POLY-3	P=0.364N	P=0.191N	P=0.250N	P=0.234N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Adrenal Medulla **Hyperplasia**				
LESION RATES				
OVERALL (a)	9/50 (18%)	11/50 (22%)	6/50 (12%)	11/50 (22%)
POLY-3 RATE (b)	9/43.09	11/44.73	6/45.90	11/40.27
POLY-3 PERCENT (g)	20.9%	24.6%	13.1%	27.3%
TERMINAL (d)	6/30 (20%)	6/30 (20%)	4/37 (11%)	6/23 (26%)
FIRST INCIDENCE	617	561	681	652
STATISTICAL TESTS				
POLY 3	P=0.381	P=0.437	P=0.242N	P=0.333
POLY 1.5	P=0.393	P=0.424	P=0.264N	P=0.351
POLY 6	P=0.366	P=0.450	P=0.219N	P=0.308
COCH-ARM / FISHERS	P=0.439	P=0.402	P=0.288N	P=0.402
MAX-ISO-POLY-3	P=0.326	P=0.342	P=0.171N	P=0.252

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Bone Marrow Hyperplasia				
LESION RATES				
OVERALL (a)	25/50 (50%)	28/50 (56%)	27/50 (54%)	28/50 (56%)
POLY-3 RATE (b)	25/46.79	28/48.85	27/47.79	28/43.29
POLY-3 PERCENT (g)	53.4%	57.3%	56.5%	64.7%
TERMINAL (d)	13/30 (43%)	13/30 (43%)	19/37 (51%)	15/23 (65%)
FIRST INCIDENCE	464	527	533	259
STATISTICAL TESTS				
POLY 3	P=0.174	P=0.430	P=0.463	P=0.186
POLY 1.5	P=0.221	P=0.396	P=0.433	P=0.233
POLY 6	P=0.127	P=0.471	P=0.492	P=0.138
COCH-ARM / FISHERS	P=0.351	P=0.344	P=0.421	P=0.344
MAX-ISO-POLY-3	P=0.243	P=0.352	P=0.382	P=0.142

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Bone: Femur
Osteopetrosis

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.38	2/43.22	1/45.64	2/39.92
POLY-3 PERCENT (g)	2.4%	4.6%	2.2%	5%
TERMINAL (d)	1/30 (3%)	1/30 (3%)	1/37 (3%)	1/23 (4%)
FIRST INCIDENCE	727 (T)	724	727 (T)	647

STATISTICAL TESTS

POLY 3	P=0.424	P=0.507	P=0.744N	P=0.479
POLY 1.5	P=0.427	P=0.505	P=0.752N	P=0.484
POLY 6	P=0.420	P=0.508	P=0.734N	P=0.472
COCH-ARM / FISHERS	P=0.444	P=0.500	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.431	P=0.288	P=0.479N	P=0.269

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Brain **Necrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	1/43.39	2/46.23	0/39.62
POLY-3 PERCENT (g)	0%	2.3%	4.3%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	681	609	---
STATISTICAL TESTS				
POLY 3	P=0.643N	P=0.505	P=0.257	(e)
POLY 1.5	P=0.636N	P=0.503	P=0.247	(e)
POLY 6	P=0.629	P=0.506	P=0.269	(e)
COCH-ARM / FISHERS	P=0.616N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.362	P=0.164	P=0.095	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Males			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Eye: Cornea **Fibrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Eye: Cornea Inflammation				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/42.38	0/43.21	0/45.64	1/39.84
POLY-3 PERCENT (g)	2.4%	0%	0%	2.5%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	727 (T)	---	---	671
STATISTICAL TESTS				
POLY 3	P=0.585	P=0.496N	P=0.485N	P=0.747
POLY 1.5	P=0.587	P=0.497N	P=0.493N	P=0.750
POLY 6	P=0.584	P=0.495N	P=0.477N	P=0.743
COCH-ARM / FISHERS	P=0.595	P=0.500N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.392	P=0.158N	P=0.158N	P=0.482

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Eye: Lens
Cataract

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/42.66	1/43.21	0/45.64	1/39.84
POLY-3 PERCENT (g)	4.7%	2.3%	0%	2.5%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	652	726	---	671

STATISTICAL TESTS

POLY 3	P=0.364N	P=0.495N	P=0.222N	P=0.524N
POLY 1.5	P=0.367N	P=0.496N	P=0.230N	P=0.518N
POLY 6	P=0.359N	P=0.496N	P=0.215N	P=0.533N
COCH-ARM / FISHERS	P=0.366N	P=0.500N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.256N	P=0.278N	P=0.076N	P=0.306N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Eye: Retina **Degeneration**				
LESION RATES				
OVERALL (a)	4/50 (8%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	4/42.69	0/43.21	0/45.64	3/39.96
POLY-3 PERCENT (g)	9.4%	0%	0%	7.5%
TERMINAL (d)	2/30 (7%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	652	---	---	647
STATISTICAL TESTS				
POLY 3	P=0.573N	P=0.058N	P=0.052N	P=0.536N
POLY 1.5	P=0.578N	P=0.059N	P=0.056N	P=0.527N
POLY 6	P=0.565N	P=0.058N	P=0.048N*	P=0.550N
COCH-ARM / FISHERS	P=0.577N	P=0.059N	P=0.059N	P=0.500N
MAX-ISO-POLY-3	P=0.094N	P=0.019N*	P=0.019N*	P=0.383N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Heart **Cardiomyopathy**				
LESION RATES				
OVERALL (a)	48/50 (96%)	50/50 (100%)	50/50 (100%)	49/50 (98%)
POLY-3 RATE (b)	48/49.26	50/50.00	50/50.00	49/49.48
POLY-3 PERCENT (g)	97.4%	100%	100%	99%
TERMINAL (d)	29/30 (97%)	30/30 (100%)	37/37 (100%)	23/23 (100%)
FIRST INCIDENCE	398	435	6	44
STATISTICAL TESTS				
POLY 3	P=0.473	P=0.397	P=0.397	P=0.576
POLY 1.5	P=0.485	P=0.322	P=0.322	P=0.554
POLY 6	P=0.412	P=0.469	P=0.469	P=0.563
COCH-ARM / FISHERS	P=0.461	P=0.247	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.135	P=0.110	P=0.110	P=0.248

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Heart: Atrium
Thrombosis

LESION RATES

OVERALL (a)	8/50 (16%)	2/50 (4%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	8/45.09	2/43.84	3/45.93	1/39.73
POLY-3 PERCENT (g)	17.7%	4.6%	6.5%	2.5%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	1/37 (3%)	0/23 (0%)
FIRST INCIDENCE	542	527	681	700

STATISTICAL TESTS

POLY 3	P=0.018N*	P=0.049N*	P=0.092N	P=0.026N*
POLY 1.5	P=0.017N*	P=0.047N*	P=0.097N	P=0.022N*
POLY 6	P=0.019N*	P=0.054N	P=0.089N	P=0.032N*
COCH-ARM / FISHERS	P=0.016N*	P=0.046N*	P=0.100N	P=0.015N*
MAX-ISO-POLY-3	P=0.012N*	P=0.025N*	P=0.050N*	P=0.015N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Intestine Large, Colon
Parasite Metazoan

LESION RATES

OVERALL (a)	12/50 (24%)	10/50 (20%)	11/50 (22%)	2/50 (4%)
POLY-3 RATE (b)	12/43.56	10/44.07	11/46.09	2/39.81
POLY-3 PERCENT (g)	27.6%	22.7%	23.9%	5%
TERMINAL (d)	8/30 (27%)	7/30 (23%)	9/37 (24%)	1/23 (4%)
FIRST INCIDENCE	570	589	633	678

STATISTICAL TESTS

POLY 3	P=0.008N**	P=0.390N	P=0.438N	P=0.005N**
POLY 1.5	P=0.007N**	P=0.393N	P=0.469N	P=0.005N**
POLY 6	P=0.010N**	P=0.393N	P=0.406N	P=0.007N**
COCH-ARM / FISHERS	P=0.005N**	P=0.405N	P=0.500N	P=0.004N**
MAX-ISO-POLY-3	P=0.011N*	P=0.301N	P=0.348N	P=0.003N**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Islets, Pancreatic **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/42.38	2/43.32	1/45.64	1/39.62
POLY-3 PERCENT (g)	0%	4.6%	2.2%	2.5%
TERMINAL (d)	0/30 (0%)	1/30 (3%)	1/37 (3%)	1/23 (4%)
FIRST INCIDENCE	---	699	727 (T)	727 (T)
STATISTICAL TESTS				
POLY 3	P=0.471	P=0.242	P=0.515	P=0.487
POLY 1.5	P=0.478	P=0.240	P=0.507	P=0.490
POLY 6	P=0.462	P=0.243	P=0.523	P=0.481
COCH-ARM / FISHERS	P=0.500	P=0.247	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.306	P=0.080	P=0.177	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Kidney
Accumulation, Hyaline Droplet

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/43.67	2/43.21	0/45.64	1/39.62
POLY-3 PERCENT (g)	4.6%	4.6%	0%	2.5%
TERMINAL (d)	0/30 (0%)	2/30 (7%)	0/37 (0%)	1/23 (4%)
FIRST INCIDENCE	464	727 (T)	---	727 (T)

STATISTICAL TESTS

POLY 3	P=0.301N	P=0.690	P=0.227N	P=0.534N
POLY 1.5	P=0.302N	P=0.692	P=0.233N	P=0.524N
POLY 6	P=0.299N	P=0.687	P=0.221N	P=0.548N
COCH-ARM / FISHERS	P=0.296N	P=0.691N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.310N	P=0.495	P=0.076N	P=0.317N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Kidney **Mineralization**				
LESION RATES				
OVERALL (a)	26/50 (52%)	31/50 (62%)	29/50 (58%)	35/50 (70%)
POLY-3 RATE (b)	26/47.47	31/47.83	29/47.46	35/47.22
POLY-3 PERCENT (g)	54.8%	64.8%	61.1%	74.1%
TERMINAL (d)	15/30 (50%)	18/30 (60%)	22/37 (60%)	16/23 (70%)
FIRST INCIDENCE	398	435	538	334
STATISTICAL TESTS				
POLY 3	P=0.040*	P=0.211	P=0.337	P=0.035*
POLY 1.5	P=0.038*	P=0.212	P=0.323	P=0.033*
POLY 6	P=0.047*	P=0.206	P=0.357	P=0.040*
COCH-ARM / FISHERS	P=0.056	P=0.210	P=0.344	P=0.050*
MAX-ISO-POLY-3	P=0.035*	P=0.155	P=0.264	P=0.022*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Kidney **Nephropathy**				
LESION RATES				
OVERALL (a)	47/50 (94%)	50/50 (100%)	50/50 (100%)	44/50 (88%)
POLY-3 RATE (b)	47/47.90	50/50.00	50/50.00	44/46.55
POLY-3 PERCENT (g)	98.1%	100%	100%	94.5%
TERMINAL (d)	30/30 (100%)	30/30 (100%)	37/37 (100%)	21/23 (91%)
FIRST INCIDENCE	398	435	6	461
STATISTICAL TESTS				
POLY 3	P=0.080N	P=0.563	P=0.563	P=0.326N
POLY 1.5	P=0.106N	P=0.246	P=0.246	P=0.367N
POLY 6	P=0.051N	P=1.000	P=1.000	P=0.260N
COCH-ARM / FISHERS	P=0.047N*	P=0.121	P=0.121	P=0.243N
MAX-ISO-POLY-3	P=0.029N*	P=0.047*	P=0.047*	P=0.141N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Males			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Kidney: Pelvis **Inflammation**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Larynx **Foreign Body**				
LESION RATES				
OVERALL (a)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.16	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Angiectasis**				
LESION RATES				
OVERALL (a)	2/50 (4%)	6/50 (12%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/42.38	6/43.21	0/45.64	1/39.62
POLY-3 PERCENT (g)	4.7%	13.9%	0%	2.5%
TERMINAL (d)	2/30 (7%)	5/30 (17%)	0/37 (0%)	1/23 (4%)
FIRST INCIDENCE	727 (T)	726	---	727 (T)
STATISTICAL TESTS				
POLY 3	P=0.137N	P=0.138	P=0.221N	P=0.523N
POLY 1.5	P=0.139N	P=0.137	P=0.229N	P=0.517N
POLY 6	P=0.136N	P=0.138	P=0.212N	P=0.533N
COCH-ARM / FISHERS	P=0.137N	P=0.134	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.086N	P=0.073	P=0.076N	P=0.306N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Basophilic Focus**				
LESION RATES				
OVERALL (a)	21/50 (42%)	23/50 (46%)	27/50 (54%)	20/50 (40%)
POLY-3 RATE (b)	21/43.18	23/43.32	27/46.18	20/39.92
POLY-3 PERCENT (g)	48.6%	53.1%	58.5%	50.1%
TERMINAL (d)	16/30 (53%)	22/30 (73%)	25/37 (68%)	18/23 (78%)
FIRST INCIDENCE	652	699	633	678
STATISTICAL TESTS				
POLY 3	P=0.472	P=0.418	P=0.230	P=0.535
POLY 1.5	P=0.512	P=0.426	P=0.189	P=0.574
POLY 6	P=0.413	P=0.391	P=0.280	P=0.468
COCH-ARM / FISHERS	P=0.452N	P=0.420	P=0.158	P=0.500N
MAX-ISO-POLY-3	P=0.477	P=0.334	P=0.178	P=0.445

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Males			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Clear Cell Focus**				
LESION RATES				
OVERALL (a)	28/50 (56%)	22/50 (44%)	25/50 (50%)	20/50 (40%)
POLY-3 RATE (b)	28/42.66	22/43.21	25/45.98	20/40.58
POLY-3 PERCENT (g)	65.6%	50.9%	54.4%	49.3%
TERMINAL (d)	27/30 (90%)	22/30 (73%)	24/37 (65%)	17/23 (74%)
FIRST INCIDENCE	652	727 (T)	633	605
STATISTICAL TESTS				
POLY 3	P=0.117N	P=0.108N	P=0.184N	P=0.085N
POLY 1.5	P=0.125N	P=0.126N	P=0.259N	P=0.091N
POLY 6	P=0.105N	P=0.092N	P=0.110N	P=0.077N
COCH-ARM / FISHERS	P=0.102N	P=0.159N	P=0.344N	P=0.080N
MAX-ISO-POLY-3	P=0.104N	P=0.072N	P=0.138N	P=0.058N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Degeneration Cystic**				
LESION RATES				
OVERALL (a)	9/50 (18%)	7/50 (14%)	5/50 (10%)	5/50 (10%)
POLY-3 RATE (b)	9/43.44	7/44.16	5/45.75	5/39.81
POLY-3 PERCENT (g)	20.7%	15.9%	10.9%	12.6%
TERMINAL (d)	6/30 (20%)	4/30 (13%)	4/37 (11%)	3/23 (13%)
FIRST INCIDENCE	559	617	699	681
STATISTICAL TESTS				
POLY 3	P=0.173N	P=0.377N	P=0.163N	P=0.241N
POLY 1.5	P=0.166N	P=0.382N	P=0.178N	P=0.226N
POLY 6	P=0.183N	P=0.374N	P=0.149N	P=0.265N
COCH-ARM / FISHERS	P=0.143N	P=0.393N	P=0.194N	P=0.194N
MAX-ISO-POLY-3	P=0.224N	P=0.280N	P=0.107N	P=0.170N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Eosinophilic Focus**				
LESION RATES				
OVERALL (a)	8/50 (16%)	7/50 (14%)	5/50 (10%)	8/50 (16%)
POLY-3 RATE (b)	8/42.91	7/43.21	5/45.64	8/40.23
POLY-3 PERCENT (g)	18.7%	16.2%	11%	19.9%
TERMINAL (d)	5/30 (17%)	7/30 (23%)	5/37 (14%)	6/23 (26%)
FIRST INCIDENCE	652	727 (T)	727 (T)	636
STATISTICAL TESTS				
POLY 3	P=0.516	P=0.494N	P=0.235N	P=0.554
POLY 1.5	P=0.521	P=0.494N	P=0.255N	P=0.567
POLY 6	P=0.508	P=0.501N	P=0.216N	P=0.533
COCH-ARM / FISHERS	P=0.555	P=0.500N	P=0.277N	P=0.607N
MAX-ISO-POLY-3	P=0.465	P=0.381N	P=0.161N	P=0.443

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Fatty Change Diffuse**				
LESION RATES				
OVERALL (a)	4/50 (8%)	3/50 (6%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	4/43.63	3/44.70	0/45.64	1/39.62
POLY-3 PERCENT (g)	9.2%	6.7%	0%	2.5%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	1/23 (4%)
FIRST INCIDENCE	542	435	---	727 (T)
STATISTICAL TESTS				
POLY 3	P=0.075N	P=0.487N	P=0.055N	P=0.209N
POLY 1.5	P=0.074N	P=0.490N	P=0.058N	P=0.199N
POLY 6	P=0.075N	P=0.488N	P=0.052N	P=0.224N
COCH-ARM / FISHERS	P=0.072N	P=0.500N	P=0.059N	P=0.181N
MAX-ISO-POLY-3	P=0.080N	P=0.337N	P=0.019N*	P=0.112N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Fatty Change Focal**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	2/39.67
POLY-3 PERCENT (g)	0%	0%	0%	5%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	1/23 (4%)
FIRST INCIDENCE	---	---	---	716
STATISTICAL TESTS				
POLY 3	P=0.043*	(e)	(e)	P=0.222
POLY 1.5	P=0.043*	(e)	(e)	P=0.226
POLY 6	P=0.043*	(e)	(e)	P=0.217
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Hematopoietic Cell Proliferation**				
LESION RATES				
OVERALL (a)	2/50 (4%)	6/50 (12%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	2/42.59	6/44.12	3/46.03	3/40.87
POLY-3 PERCENT (g)	4.7%	13.6%	6.5%	7.3%
TERMINAL (d)	1/30 (3%)	3/30 (10%)	1/37 (3%)	1/23 (4%)
FIRST INCIDENCE	671	539	652	259
STATISTICAL TESTS				
POLY 3	P=0.556N	P=0.143	P=0.535	P=0.481
POLY 1.5	P=0.553N	P=0.140	P=0.518	P=0.486
POLY 6	P=0.561N	P=0.146	P=0.555	P=0.472
COCH-ARM / FISHERS	P=0.537N	P=0.134	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.382	P=0.079	P=0.360	P=0.310

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Hepatodiaphragmatic Nodule**				
LESION RATES				
OVERALL (a)	3/50 (6%)	6/50 (12%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	3/42.93	6/45.20	1/45.64	4/39.65
POLY-3 PERCENT (g)	7%	13.3%	2.2%	10.1%
TERMINAL (d)	2/30 (7%)	2/30 (7%)	1/37 (3%)	3/23 (13%)
FIRST INCIDENCE	559	435	727 (T)	720
STATISTICAL TESTS				
POLY 3	P=0.562N	P=0.267	P=0.283N	P=0.457
POLY 1.5	P=0.558N	P=0.259	P=0.295N	P=0.469
POLY 6	P=0.567N	P=0.277	P=0.271N	P=0.438
COCH-ARM / FISHERS	P=0.537N	P=0.243	P=0.309N	P=0.500
MAX-ISO-POLY-3	P=0.400N	P=0.172	P=0.146N	P=0.314

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver Inflammation				
LESION RATES				
OVERALL (a)	35/50 (70%)	34/50 (68%)	41/50 (82%)	32/50 (64%)
POLY-3 RATE (b)	35/45.53	34/44.98	41/47.90	32/44.62
POLY-3 PERCENT (g)	76.9%	75.6%	85.6%	71.7%
TERMINAL (d)	25/30 (83%)	27/30 (90%)	35/37 (95%)	20/23 (87%)
FIRST INCIDENCE	398	435	533	461
STATISTICAL TESTS				
POLY 3	P=0.369N	P=0.545N	P=0.191	P=0.368N
POLY 1.5	P=0.417N	P=0.517N	P=0.136	P=0.391N
POLY 6	P=0.303N	P=0.609N	P=0.273	P=0.340N
COCH-ARM / FISHERS	P=0.356N	P=0.500N	P=0.121	P=0.335N
MAX-ISO-POLY-3	P=0.282N	P=0.437N	P=0.129	P=0.279N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Mixed Cell Focus**				
LESION RATES				
OVERALL (a)	4/50 (8%)	1/50 (2%)	1/50 (2%)	5/50 (10%)
POLY-3 RATE (b)	4/42.38	1/43.21	1/45.84	5/39.83
POLY-3 PERCENT (g)	9.4%	2.3%	2.2%	12.6%
TERMINAL (d)	4/30 (13%)	1/30 (3%)	0/37 (0%)	4/23 (17%)
FIRST INCIDENCE	727 (T)	727 (T)	676	673
STATISTICAL TESTS				
POLY 3	P=0.268	P=0.172N	P=0.155N	P=0.461
POLY 1.5	P=0.269	P=0.174N	P=0.167N	P=0.470
POLY 6	P=0.268	P=0.170N	P=0.143N	P=0.447
COCH-ARM / FISHERS	P=0.282	P=0.181N	P=0.181N	P=0.500
MAX-ISO-POLY-3	P=0.124	P=0.081N	P=0.078N	P=0.331

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Necrosis**				
LESION RATES				
OVERALL (a)	6/50 (12%)	4/50 (8%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	6/44.07	4/44.55	1/45.82	2/40.69
POLY-3 PERCENT (g)	13.6%	9%	2.2%	4.9%
TERMINAL (d)	2/30 (7%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	464	539	681	259
STATISTICAL TESTS				
POLY 3	P=0.072N	P=0.362N	P=0.050N*	P=0.159N
POLY 1.5	P=0.071N	P=0.364N	P=0.053N	P=0.150N
POLY 6	P=0.073N	P=0.362N	P=0.046N*	P=0.173N
COCH-ARM / FISHERS	P=0.066N	P=0.370N	P=0.056N	P=0.134N
MAX-ISO-POLY-3	P=0.070N	P=0.247N	P=0.022N*	P=0.093N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Pigmentation Hemosiderin**				
LESION RATES				
OVERALL (a)	1/50 (2%)	4/50 (8%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/42.59	4/43.69	0/45.64	0/39.62
POLY-3 PERCENT (g)	2.4%	9.2%	0%	0%
TERMINAL (d)	0/30 (0%)	1/30 (3%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	671	629	---	---
STATISTICAL TESTS				
POLY 3	P=0.126N	P=0.186	P=0.486N	P=0.514N
POLY 1.5	P=0.127N	P=0.184	P=0.493N	P=0.510N
POLY 6	P=0.126N	P=0.188	P=0.479N	P=0.521N
COCH-ARM / FISHERS	P=0.125N	P=0.181	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.106N	P=0.091	P=0.158N	P=0.176N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver: Bile Duct Hyperplasia				
LESION RATES				
OVERALL (a)	47/50 (94%)	49/50 (98%)	44/50 (88%)	39/50 (78%)
POLY-3 RATE (b)	47/48.42	49/50.00	44/48.14	39/44.17
POLY-3 PERCENT (g)	97.1%	98%	91.4%	88.3%
TERMINAL (d)	29/30 (97%)	29/30 (97%)	35/37 (95%)	23/23 (100%)
FIRST INCIDENCE	440	435	538	461
STATISTICAL TESTS				
POLY 3	P=0.018N*	P=0.645	P=0.209N	P=0.071N
POLY 1.5	P=0.007N**	P=0.514	P=0.242N	P=0.044N*
POLY 6	P=0.063N	P=0.729	P=0.211N	P=0.165N
COCH-ARM / FISHERS	P<0.001N**	P=0.309	P=0.243N	P=0.020N*
MAX-ISO-POLY-3	P=0.026N*	P=0.375	P=0.101N	P=0.031N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver: Centrilobular Degeneration				
LESION RATES				
OVERALL (a)	3/50 (6%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	3/43.23	2/43.81	1/45.75	0/39.62
POLY-3 PERCENT (g)	6.9%	4.6%	2.2%	0%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	542	539	699	---
STATISTICAL TESTS				
POLY 3	P=0.067N	P=0.494N	P=0.285N	P=0.135N
POLY 1.5	P=0.066N	P=0.495N	P=0.296N	P=0.130N
POLY 6	P=0.068N	P=0.495N	P=0.274N	P=0.142N
COCH-ARM / FISHERS	P=0.062N	P=0.500N	P=0.309N	P=0.121N
MAX-ISO-POLY-3	P=0.083N	P=0.319N	P=0.146N	P=0.051N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver: Oval Cell Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	1/39.92
POLY-3 PERCENT (g)	0%	0%	0%	2.5%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	647
STATISTICAL TESTS				
POLY 3	P=0.190	(e)	(e)	P=0.488
POLY 1.5	P=0.192	(e)	(e)	P=0.491
POLY 6	P=0.188	(e)	(e)	P=0.484
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.123	(e)	(e)	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Males			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung Congestion				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung **Fibrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/42.38	2/43.82	1/45.91	2/39.62
POLY-3 PERCENT (g)	0%	4.6%	2.2%	5.1%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	2/23 (9%)
FIRST INCIDENCE	---	576	657	727 (T)
STATISTICAL TESTS				
POLY 3	P=0.226	P=0.244	P=0.516	P=0.222
POLY 1.5	P=0.230	P=0.242	P=0.508	P=0.226
POLY 6	P=0.220	P=0.247	P=0.525	P=0.216
COCH-ARM / FISHERS	P=0.245	P=0.247	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.159	P=0.083	P=0.178	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung **Inflammation**				
LESION RATES				
OVERALL (a)	4/50 (8%)	8/50 (16%)	3/50 (6%)	8/50 (16%)
POLY-3 RATE (b)	4/43.76	8/45.83	3/45.82	8/41.46
POLY-3 PERCENT (g)	9.1%	17.5%	6.6%	19.3%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	2/37 (5%)	3/23 (13%)
FIRST INCIDENCE	559	527	681	44
STATISTICAL TESTS				
POLY 3	P=0.208	P=0.199	P=0.475N	P=0.149
POLY 1.5	P=0.218	P=0.191	P=0.488N	P=0.159
POLY 6	P=0.197	P=0.210	P=0.461N	P=0.136
COCH-ARM / FISHERS	P=0.238	P=0.178	P=0.500N	P=0.178
MAX-ISO-POLY-3	P=0.143	P=0.129	P=0.328N	P=0.094

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung **Thrombosis**				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/43.66	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	6.9%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	533	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.042N*	P=0.120N	P=0.111N	P=0.137N
POLY 1.5	P=0.044N*	P=0.119N	P=0.115N	P=0.131N
POLY 6	P=0.040N*	P=0.123N	P=0.107N	P=0.146N
COCH-ARM / FISHERS	P=0.047N*	P=0.121N	P=0.121N	P=0.121N
MAX-ISO-POLY-3	P=0.017N*	P=0.039N*	P=0.038N*	P=0.053N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Lung: Alveolar Epithelium
Hyperplasia

LESION RATES

OVERALL (a)	10/50 (20%)	7/50 (14%)	7/50 (14%)	6/50 (12%)
POLY-3 RATE (b)	10/43.13	7/43.22	7/45.70	6/40.13
POLY-3 PERCENT (g)	23.2%	16.2%	15.3%	15%
TERMINAL (d)	8/30 (27%)	6/30 (20%)	6/37 (16%)	4/23 (17%)
FIRST INCIDENCE	559	724	713	636

STATISTICAL TESTS

POLY 3	P=0.223N	P=0.292N	P=0.251N	P=0.249N
POLY 1.5	P=0.219N	P=0.292N	P=0.274N	P=0.238N
POLY 6	P=0.229N	P=0.297N	P=0.226N	P=0.266N
COCH-ARM / FISHERS	P=0.192N	P=0.298N	P=0.298N	P=0.207N
MAX-ISO-POLY-3	P=0.280N	P=0.207N	P=0.180N	P=0.178N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung: Alveolar Epithelium Metaplasia				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	2/42.38	0/43.21	3/45.84	1/39.95
POLY-3 PERCENT (g)	4.7%	0%	6.5%	2.5%
TERMINAL (d)	2/30 (7%)	0/30 (0%)	2/37 (5%)	0/23 (0%)
FIRST INCIDENCE	727 (T)	---	676	636
STATISTICAL TESTS				
POLY 3	P=0.582N	P=0.233N	P=0.536	P=0.521N
POLY 1.5	P=0.576N	P=0.234N	P=0.518	P=0.516N
POLY 6	P=0.588N	P=0.232N	P=0.556	P=0.527N
COCH-ARM / FISHERS	P=0.556N	P=0.247N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.469	P=0.076N	P=0.361	P=0.303N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Lung: Alveolus
Infiltration Cellular Histiocyte

LESION RATES

OVERALL (a)	15/50 (30%)	14/50 (28%)	18/50 (36%)	19/50 (38%)
POLY-3 RATE (b)	15/44.17	14/45.55	18/47.22	19/42.74
POLY-3 PERCENT (g)	34%	30.7%	38.1%	44.5%
TERMINAL (d)	10/30 (33%)	5/30 (17%)	14/37 (38%)	10/23 (44%)
FIRST INCIDENCE	464	527	6	524

STATISTICAL TESTS

POLY 3	P=0.126	P=0.460N	P=0.422	P=0.214
POLY 1.5	P=0.131	P=0.475N	P=0.389	P=0.220
POLY 6	P=0.120	P=0.443N	P=0.458	P=0.206
COCH-ARM / FISHERS	P=0.167	P=0.500N	P=0.335	P=0.263
MAX-ISO-POLY-3	P=0.202	P=0.372N	P=0.343	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node, Mesenteric **Atrophy**				
LESION RATES				
OVERALL (a)	3/49 (6%)	6/50 (12%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	3/41.97	6/43.33	3/45.64	4/40.01
POLY-3 PERCENT (g)	7.2%	13.9%	6.6%	10%
TERMINAL (d)	2/29 (7%)	4/30 (13%)	3/37 (8%)	3/23 (13%)
FIRST INCIDENCE	542	701	727 (T)	617
STATISTICAL TESTS				
POLY 3	P=0.542	P=0.257	P=0.623N	P=0.474
POLY 1.5	P=0.549	P=0.256	P=0.638N	P=0.483
POLY 6	P=0.533	P=0.256	P=0.606N	P=0.461
COCH-ARM / FISHERS	P=0.560N	P=0.254	P=0.651N	P=0.511
MAX-ISO-POLY-3	P=0.528	P=0.160	P=0.458N	P=0.328

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node, Mesenteric **Ectasia**				
LESION RATES				
OVERALL (a)	1/49 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/41.77	2/43.52	0/45.64	0/39.62
POLY-3 PERCENT (g)	2.4%	4.6%	0%	0%
TERMINAL (d)	0/29 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	617	645	---	---
STATISTICAL TESTS				
POLY 3	P=0.186N	P=0.514	P=0.482N	P=0.511N
POLY 1.5	P=0.187N	P=0.512	P=0.489N	P=0.506N
POLY 6	P=0.185N	P=0.516	P=0.475N	P=0.517N
COCH-ARM / FISHERS	P=0.185N	P=0.508	P=0.495N	P=0.495N
MAX-ISO-POLY-3	P=0.202N	P=0.295	P=0.157N	P=0.173N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node, Mesenteric **Hyperplasia Lymphoid**				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/41.38	0/43.21	0/45.64	1/40.02
POLY-3 PERCENT (g)	0%	0%	0%	2.5%
TERMINAL (d)	0/29 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	613
STATISTICAL TESTS				
POLY 3	P=0.192	(e)	(e)	P=0.493
POLY 1.5	P=0.194	(e)	(e)	P=0.496
POLY 6	P=0.190	(e)	(e)	P=0.490
COCH-ARM / FISHERS	P=0.200	(e)	(e)	P=0.505
MAX-ISO-POLY-3	P=0.124	(e)	(e)	P=0.160

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node: Mediastinal				
Ectasia				
LESION RATES				
OVERALL (a)	2/7 (29%)	0/15 (0%)	0/4 (0%)	0/6 (0%)
POLY-3 RATE (b)	2/5.88	0/11.97	0/3.74	0/5.49
POLY-3 PERCENT (g)	34%	0%	0%	0%
TERMINAL (d)	1/3 (33%)	0/5 (0%)	0/2 (0%)	0/2 (0%)
FIRST INCIDENCE	673	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.120N	P=0.071N	P=0.324N	P=0.228N
POLY 1.5	P=0.125N	P=0.070N	P=0.339N	P=0.239N
POLY 6	P=0.111N	P=0.075N	P=0.312N	P=0.220N
COCH-ARM / FISHERS	P=0.147N	P=0.091N	P=0.382N	P=0.269N
MAX-ISO-POLY-3	P=0.012N*	P=0.021N*	P=0.119N	P=0.062N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node: Mediastinal **Hyperplasia Lymphoid**				
LESION RATES				
OVERALL (a)	1/7 (14%)	0/15 (0%)	0/4 (0%)	1/6 (17%)
POLY-3 RATE (b)	1/5.67	0/11.97	0/3.74	1/5.49
POLY-3 PERCENT (g)	17.6%	0%	0%	18.2%
TERMINAL (d)	1/3 (33%)	0/5 (0%)	0/2 (0%)	1/2 (50%)
FIRST INCIDENCE	727 (T)	---	---	727 (T)
STATISTICAL TESTS				
POLY 3	P=0.510	P=0.345N	P=0.584N	P=0.759
POLY 1.5	P=0.499	P=0.344N	P=0.595N	P=0.745
POLY 6	P=0.525	P=0.348N	P=0.571N	P=0.764N
COCH-ARM / FISHERS	P=0.486	P=0.318N	P=0.636N	P=0.731
MAX-ISO-POLY-3	P=0.322	P=0.096N	P=0.221N	P=0.490

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Lymph Node: Mediastinal
Infiltration Cellular Plasma Cell

LESION RATES

OVERALL (a)	1/7 (14%)	3/15 (20%)	1/4 (25%)	0/6 (0%)
POLY-3 RATE (b)	1/5.70	3/12.38	1/3.82	0/5.49
POLY-3 PERCENT (g)	17.5%	24.2%	26.2%	0%
TERMINAL (d)	0/3 (0%)	1/5 (20%)	0/2 (0%)	0/2 (0%)
FIRST INCIDENCE	719	645	707	---

STATISTICAL TESTS

POLY 3	P=0.273N	P=0.611	P=0.677	P=0.508N
POLY 1.5	P=0.292N	P=0.607	P=0.658	P=0.517N
POLY 6	P=0.252N	P=0.616	P=0.700	P=0.498N
COCH-ARM / FISHERS	P=0.313N	P=0.622	P=0.618	P=0.538N
MAX-ISO-POLY-3	P=0.277N	P=0.394	P=0.387	P=0.165N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node: Pancreatic				
Ectasia				
LESION RATES				
OVERALL (a)	0/7 (0%)	2/15 (13%)	1/4 (25%)	0/6 (0%)
POLY-3 RATE (b)	0/5.67	2/11.98	1/3.82	0/5.49
POLY-3 PERCENT (g)	0%	16.7%	26.2%	0%
TERMINAL (d)	0/3 (0%)	1/5 (20%)	0/2 (0%)	0/2 (0%)
FIRST INCIDENCE	---	724	707	---
STATISTICAL TESTS				
POLY 3	P=0.558N	P=0.410	P=0.416	(e)
POLY 1.5	P=0.577N	P=0.413	P=0.402	(e)
POLY 6	P=0.535N	P=0.404	P=0.435	(e)
COCH-ARM / FISHERS	P=0.605N	P=0.455	P=0.364	(e)
MAX-ISO-POLY-3	P=0.377	P=0.190	P=0.109	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Mammary Gland Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Mesentery: Fat Necrosis				
LESION RATES				
OVERALL (a)	11/13 (85%)	8/9 (89%)	4/6 (67%)	4/5 (80%)
POLY-3 RATE (b)	11/11.67	8/8.41	4/5.89	4/5.00
POLY-3 PERCENT (g)	94.2%	95.2%	67.9%	80%
TERMINAL (d)	4/4 (100%)	4/4 (100%)	3/4 (75%)	2/3 (67%)
FIRST INCIDENCE	533	561	681	647
STATISTICAL TESTS				
POLY 3	P=0.200N	P=0.914	P=0.193N	P=0.502N
POLY 1.5	P=0.292N	P=0.773	P=0.270N	P=0.587N
POLY 6	P=0.124N	P=1.000	P=0.133N	P=0.394N
COCH-ARM / FISHERS	P=0.429N	P=0.642	P=0.373N	P=0.650N
MAX-ISO-POLY-3	P=0.207N	P=0.448	P=0.069N	P=0.194N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Nose **Foreign Body**				
LESION RATES				
OVERALL (a)	7/50 (14%)	7/50 (14%)	9/50 (18%)	5/50 (10%)
POLY-3 RATE (b)	7/42.59	7/43.40	9/45.98	5/41.56
POLY-3 PERCENT (g)	16.4%	16.1%	19.6%	12%
TERMINAL (d)	6/30 (20%)	4/30 (13%)	8/37 (22%)	1/23 (4%)
FIRST INCIDENCE	673	681	633	259
STATISTICAL TESTS				
POLY 3	P=0.358N	P=0.600N	P=0.458	P=0.395N
POLY 1.5	P=0.357N	P=0.603N	P=0.425	P=0.393N
POLY 6	P=0.365N	P=0.598N	P=0.495	P=0.404N
COCH-ARM / FISHERS	P=0.340N	P=0.613N	P=0.393	P=0.380N
MAX-ISO-POLY-3	P=0.414N	P=0.484N	P=0.355	P=0.285N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Nose: Olfactory Epithelium Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	0/42.38	2/43.21	2/45.64	4/40.98
POLY-3 PERCENT (g)	0%	4.6%	4.4%	9.8%
TERMINAL (d)	0/30 (0%)	2/30 (7%)	2/37 (5%)	1/23 (4%)
FIRST INCIDENCE	---	727 (T)	727 (T)	44
STATISTICAL TESTS				
POLY 3	P=0.040*	P=0.241	P=0.254	P=0.055
POLY 1.5	P=0.041*	P=0.240	P=0.246	P=0.057
POLY 6	P=0.038*	P=0.242	P=0.264	P=0.053
COCH-ARM / FISHERS	P=0.044*	P=0.247	P=0.247	P=0.059
MAX-ISO-POLY-3	P=0.030*	P=0.080	P=0.092	P=0.019*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Nose: Respiratory Epithelium
Inflammation

LESION RATES

OVERALL (a)	12/50 (24%)	11/50 (22%)	10/50 (20%)	16/50 (32%)
POLY-3 RATE (b)	12/42.80	11/43.52	10/46.23	16/43.22
POLY-3 PERCENT (g)	28%	25.3%	21.6%	37%
TERMINAL (d)	10/30 (33%)	6/30 (20%)	6/37 (16%)	4/23 (17%)
FIRST INCIDENCE	671	681	633	259

STATISTICAL TESTS

POLY 3	P=0.183	P=0.481N	P=0.325N	P=0.253
POLY 1.5	P=0.174	P=0.486N	P=0.364N	P=0.244
POLY 6	P=0.195	P=0.480N	P=0.282N	P=0.264
COCH-ARM / FISHERS	P=0.180	P=0.500N	P=0.405N	P=0.252
MAX-ISO-POLY-3	P=0.169	P=0.385N	P=0.250N	P=0.186

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Pancreas **Atrophy**				
LESION RATES				
OVERALL (a)	24/50 (48%)	22/50 (44%)	23/50 (46%)	22/50 (44%)
POLY-3 RATE (b)	24/43.66	22/45.45	23/47.48	22/42.93
POLY-3 PERCENT (g)	55%	48.4%	48.4%	51.2%
TERMINAL (d)	19/30 (63%)	14/30 (47%)	17/37 (46%)	11/23 (48%)
FIRST INCIDENCE	559	539	533	461
STATISTICAL TESTS				
POLY 3	P=0.448N	P=0.338N	P=0.338N	P=0.446N
POLY 1.5	P=0.461N	P=0.369N	P=0.416N	P=0.459N
POLY 6	P=0.425N	P=0.307N	P=0.254N	P=0.425N
COCH-ARM / FISHERS	P=0.414N	P=0.421N	P=0.500N	P=0.421N
MAX-ISO-POLY-3	P=0.482N	P=0.267N	P=0.273N	P=0.361N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Pancreas **Inflammation**				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.22	2/43.56	0/45.64	0/39.62
POLY-3 PERCENT (g)	2.3%	4.6%	0%	0%
TERMINAL (d)	0/30 (0%)	1/30 (3%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	398	629	---	---
STATISTICAL TESTS				
POLY 3	P=0.192N	P=0.503	P=0.489N	P=0.517N
POLY 1.5	P=0.192N	P=0.502	P=0.495N	P=0.513N
POLY 6	P=0.190N	P=0.504	P=0.482N	P=0.524N
COCH-ARM / FISHERS	P=0.188N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.208N	P=0.283	P=0.158N	P=0.180N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

			Males	
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Pancreas: Acinus
Hyperplasia

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	1/42.56	0/43.21	2/45.64	3/40.11
POLY-3 PERCENT (g)	2.4%	0%	4.4%	7.5%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	2/37 (5%)	1/23 (4%)
FIRST INCIDENCE	682	---	727 (T)	652

STATISTICAL TESTS

POLY 3	P=0.092	P=0.497N	P=0.524	P=0.284
POLY 1.5	P=0.094	P=0.498N	P=0.512	P=0.289
POLY 6	P=0.090	P=0.497N	P=0.538	P=0.277
COCH-ARM / FISHERS	P=0.104	P=0.500N	P=0.500	P=0.309
MAX-ISO-POLY-3	P=0.107	P=0.158N	P=0.307	P=0.146

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Parathyroid Gland Hyperplasia				
LESION RATES				
OVERALL (a)	1/50 (2%)	3/49 (6%)	0/49 (0%)	1/46 (2%)
POLY-3 RATE (b)	1/42.38	3/42.31	0/44.64	1/37.43
POLY-3 PERCENT (g)	2.4%	7.1%	0%	2.7%
TERMINAL (d)	1/30 (3%)	2/29 (7%)	0/36 (0%)	0/22 (0%)
FIRST INCIDENCE	727 (T)	701	---	617
STATISTICAL TESTS				
POLY 3	P=0.432N	P=0.304	P=0.490N	P=0.733
POLY 1.5	P=0.437N	P=0.303	P=0.497N	P=0.734
POLY 6	P=0.427N	P=0.305	P=0.481N	P=0.732
COCH-ARM / FISHERS	P=0.435N	P=0.301	P=0.505N	P=0.731
MAX-ISO-POLY-3	P=0.312N	P=0.154	P=0.160N	P=0.465

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Pituitary Gland: Pars Distalis
Angiectasis

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/42.38	3/44.01	1/45.64	1/39.62
POLY-3 PERCENT (g)	4.7%	6.8%	2.2%	2.5%
TERMINAL (d)	2/30 (7%)	1/30 (3%)	1/37 (3%)	1/23 (4%)
FIRST INCIDENCE	727 (T)	576	727 (T)	727 (T)

STATISTICAL TESTS

POLY 3	P=0.293N	P=0.517	P=0.474N	P=0.523N
POLY 1.5	P=0.291N	P=0.511	P=0.487N	P=0.517N
POLY 6	P=0.294N	P=0.525	P=0.460N	P=0.533N
COCH-ARM / FISHERS	P=0.279N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.371N	P=0.341	P=0.266N	P=0.306N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Pituitary Gland: Pars Distalis				
Cyst				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Pituitary Gland: Pars Distalis
Hyperplasia

LESION RATES

OVERALL (a)	16/50 (32%)	20/50 (40%)	18/50 (36%)	21/50 (42%)
POLY-3 RATE (b)	16/44.07	20/46.44	18/46.90	21/43.24
POLY-3 PERCENT (g)	36.3%	43.1%	38.4%	48.6%
TERMINAL (d)	12/30 (40%)	12/30 (40%)	14/37 (38%)	11/23 (48%)
FIRST INCIDENCE	464	527	533	461

STATISTICAL TESTS

POLY 3	P=0.180	P=0.328	P=0.505	P=0.168
POLY 1.5	P=0.181	P=0.303	P=0.458	P=0.169
POLY 6	P=0.179	P=0.357	P=0.560	P=0.167
COCH-ARM / FISHERS	P=0.222	P=0.266	P=0.417	P=0.204
MAX-ISO-POLY-3	P=0.202	P=0.259	P=0.419	P=0.121

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Preputial Gland Inflammation				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.90	1/43.21	1/45.64	2/39.62
POLY-3 PERCENT (g)	2.3%	2.3%	2.2%	5.1%
TERMINAL (d)	0/30 (0%)	1/30 (3%)	1/37 (3%)	2/23 (9%)
FIRST INCIDENCE	570	727 (T)	727 (T)	727 (T)
STATISTICAL TESTS				
POLY 3	P=0.328	P=0.759N	P=0.747N	P=0.472
POLY 1.5	P=0.334	P=0.759N	P=0.754N	P=0.480
POLY 6	P=0.321	P=0.760N	P=0.739N	P=0.461
COCH-ARM / FISHERS	P=0.351	P=0.753N	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.391	P=0.497N	P=0.482N	P=0.265

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Prostate Inflammation				
LESION RATES				
OVERALL (a)	26/50 (52%)	29/50 (58%)	20/50 (40%)	21/50 (42%)
POLY-3 RATE (b)	26/46.39	29/46.31	20/47.14	21/43.55
POLY-3 PERCENT (g)	56.1%	62.6%	42.4%	48.2%
TERMINAL (d)	14/30 (47%)	18/30 (60%)	15/37 (41%)	8/23 (35%)
FIRST INCIDENCE	398	539	533	524
STATISTICAL TESTS				
POLY 3	P=0.130N	P=0.330	P=0.130N	P=0.295N
POLY 1.5	P=0.126N	P=0.336	P=0.148N	P=0.279N
POLY 6	P=0.133N	P=0.320	P=0.115N	P=0.311N
COCH-ARM / FISHERS	P=0.090N	P=0.344	P=0.158N	P=0.212N
MAX-ISO-POLY-3	P=0.149N	P=0.256	P=0.093N	P=0.233N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Prostate: Epithelium
Hyperplasia

LESION RATES

OVERALL (a)	3/50 (6%)	7/50 (14%)	8/50 (16%)	4/50 (8%)
POLY-3 RATE (b)	3/42.38	7/43.52	8/45.94	4/39.62
POLY-3 PERCENT (g)	7.1%	16.1%	17.4%	10.1%
TERMINAL (d)	3/30 (10%)	5/30 (17%)	6/37 (16%)	4/23 (17%)
FIRST INCIDENCE	727 (T)	645	663	727 (T)

STATISTICAL TESTS

POLY 3	P=0.463	P=0.166	P=0.125	P=0.463
POLY 1.5	P=0.479	P=0.164	P=0.111	P=0.473
POLY 6	P=0.441	P=0.169	P=0.142	P=0.449
COCH-ARM / FISHERS	P=0.530	P=0.159	P=0.100	P=0.500
MAX-ISO-POLY-3	P=0.263	P=0.098	P=0.078	P=0.319

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Skin: Epidermis
Cyst Epithelial Inclusion

LESION RATES

OVERALL (a)	2/50 (4%)	5/50 (10%)	6/50 (12%)	7/50 (14%)
POLY-3 RATE (b)	2/42.68	5/43.54	6/45.72	7/41.10
POLY-3 PERCENT (g)	4.7%	11.5%	13.1%	17%
TERMINAL (d)	1/30 (3%)	3/30 (10%)	5/37 (14%)	2/23 (9%)
FIRST INCIDENCE	646	666	707	551

STATISTICAL TESTS

POLY 3	P=0.064	P=0.223	P=0.156	P=0.068
POLY 1.5	P=0.065	P=0.222	P=0.144	P=0.070
POLY 6	P=0.062	P=0.224	P=0.169	P=0.066
COCH-ARM / FISHERS	P=0.076	P=0.218	P=0.134	P=0.080
MAX-ISO-POLY-3	P=0.068	P=0.127	P=0.091	P=0.035*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Skin: Epidermis **Hyperplasia**				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/42.45	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	4.7%	0%	0%	0%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	709	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.109N	P=0.233N	P=0.221N	P=0.253N
POLY 1.5	P=0.111N	P=0.234N	P=0.229N	P=0.249N
POLY 6	P=0.105N	P=0.232N	P=0.213N	P=0.259N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.045N*	P=0.076N	P=0.076N	P=0.091N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Spleen
Hematopoietic Cell Proliferation

LESION RATES

OVERALL (a)	29/50 (58%)	26/50 (52%)	33/50 (66%)	26/50 (52%)
POLY-3 RATE (b)	29/45.68	26/44.85	33/48.12	26/43.45
POLY-3 PERCENT (g)	63.5%	58%	68.6%	59.8%
TERMINAL (d)	20/30 (67%)	20/30 (67%)	26/37 (70%)	15/23 (65%)
FIRST INCIDENCE	464	527	6	259

STATISTICAL TESTS

POLY 3	P=0.498N	P=0.370N	P=0.378	P=0.444N
POLY 1.5	P=0.478N	P=0.351N	P=0.335	P=0.414N
POLY 6	P=0.534N	P=0.413N	P=0.425	P=0.500N
COCH-ARM / FISHERS	P=0.405N	P=0.344N	P=0.268	P=0.344N
MAX-ISO-POLY-3	P=0.567	P=0.292N	P=0.301	P=0.359N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Spleen **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	2/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/30 (0%)	2/30 (7%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	727 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.405N	P=0.241	(e)	(e)
POLY 1.5	P=0.407N	P=0.240	(e)	(e)
POLY 6	P=0.403N	P=0.242	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.281N	P=0.080	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Spleen **Necrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/42.38	2/43.94	1/45.82	1/39.62
POLY-3 PERCENT (g)	0%	4.6%	2.2%	2.5%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	1/23 (4%)
FIRST INCIDENCE	---	576	681	727 (T)
STATISTICAL TESTS				
POLY 3	P=0.471	P=0.245	P=0.516	P=0.487
POLY 1.5	P=0.478	P=0.242	P=0.508	P=0.490
POLY 6	P=0.462	P=0.248	P=0.525	P=0.481
COCH-ARM / FISHERS	P=0.500	P=0.247	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.309	P=0.083	P=0.178	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Spleen
Pigmentation Hemosiderin

LESION RATES

OVERALL (a)	30/50 (60%)	30/50 (60%)	31/50 (62%)	31/50 (62%)
POLY-3 RATE (b)	30/45.15	30/45.53	31/47.90	31/45.01
POLY-3 PERCENT (g)	66.5%	65.9%	64.7%	68.9%
TERMINAL (d)	22/30 (73%)	23/30 (77%)	25/37 (68%)	18/23 (78%)
FIRST INCIDENCE	398	435	533	334

STATISTICAL TESTS

POLY 3	P=0.438	P=0.569N	P=0.517N	P=0.491
POLY 1.5	P=0.405	P=0.570N	P=0.571	P=0.466
POLY 6	P=0.477	P=0.576N	P=0.413N	P=0.518
COCH-ARM / FISHERS	P=0.442	P=0.581N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.583	P=0.475N	P=0.429N	P=0.397

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Stomach, Forestomach **Inflammation**				
LESION RATES				
OVERALL (a)	5/50 (10%)	3/50 (6%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	5/43.59	3/44.77	1/45.82	2/40.19
POLY-3 PERCENT (g)	11.5%	6.7%	2.2%	5%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	559	435	681	617
STATISTICAL TESTS				
POLY 3	P=0.146N	P=0.341N	P=0.090N	P=0.249N
POLY 1.5	P=0.144N	P=0.346N	P=0.096N	P=0.240N
POLY 6	P=0.147N	P=0.341N	P=0.085N	P=0.264N
COCH-ARM / FISHERS	P=0.135N	P=0.357N	P=0.102N	P=0.218N
MAX-ISO-POLY-3	P=0.124N	P=0.222N	P=0.042N*	P=0.151N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Stomach, Forestomach				
Necrosis				
LESION RATES				
OVERALL (a)	3/50 (6%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	3/43.05	1/44.00	0/45.64	1/40.01
POLY-3 PERCENT (g)	7%	2.3%	0%	2.5%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	650	435	---	617
STATISTICAL TESTS				
POLY 3	P=0.199N	P=0.297N	P=0.108N	P=0.331N
POLY 1.5	P=0.201N	P=0.299N	P=0.114N	P=0.324N
POLY 6	P=0.196N	P=0.299N	P=0.104N	P=0.343N
COCH-ARM / FISHERS	P=0.200N	P=0.309N	P=0.121N	P=0.309N
MAX-ISO-POLY-3	P=0.106N	P=0.150N	P=0.038N*	P=0.181N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Stomach, Forestomach: Epithelium
Hyperplasia

LESION RATES

OVERALL (a)	4/50 (8%)	2/50 (4%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	4/43.05	2/44.23	0/45.64	3/41.05
POLY-3 PERCENT (g)	9.3%	4.5%	0%	7.3%
TERMINAL (d)	1/30 (3%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	650	435	---	259

STATISTICAL TESTS

POLY 3	P=0.434N	P=0.324N	P=0.053N	P=0.526N
POLY 1.5	P=0.436N	P=0.328N	P=0.057N	P=0.518N
POLY 6	P=0.431N	P=0.324N	P=0.050N*	P=0.540N
COCH-ARM / FISHERS	P=0.431N	P=0.339N	P=0.059N	P=0.500N
MAX-ISO-POLY-3	P=0.196N	P=0.193N	P=0.019N*	P=0.373N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Stomach, Glandular Inflammation				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/42.76	1/43.44	0/45.64	0/39.62
POLY-3 PERCENT (g)	4.7%	2.3%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	673	666	---	---
STATISTICAL TESTS				
POLY 3	P=0.099N	P=0.494N	P=0.223N	P=0.254N
POLY 1.5	P=0.101N	P=0.496N	P=0.230N	P=0.249N
POLY 6	P=0.097N	P=0.495N	P=0.216N	P=0.262N
COCH-ARM / FISHERS	P=0.101N	P=0.500N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.099N	P=0.277N	P=0.076N	P=0.092N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Stomach, Glandular **Necrosis**				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.14	1/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	4.6%	2.3%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	542	726	---	---
STATISTICAL TESTS				
POLY 3	P=0.099N	P=0.499N	P=0.225N	P=0.256N
POLY 1.5	P=0.101N	P=0.499N	P=0.231N	P=0.251N
POLY 6	P=0.097N	P=0.502N	P=0.218N	P=0.265N
COCH-ARM / FISHERS	P=0.101N	P=0.500N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.102N	P=0.280N	P=0.076N	P=0.094N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Testes: Interstitial Cell Hyperplasia				
LESION RATES				
OVERALL (a)	13/50 (26%)	12/50 (24%)	11/50 (22%)	9/50 (18%)
POLY-3 RATE (b)	13/45.58	12/46.12	11/46.43	9/41.39
POLY-3 PERCENT (g)	28.5%	26%	23.7%	21.8%
TERMINAL (d)	5/30 (17%)	4/30 (13%)	8/37 (22%)	3/23 (13%)
FIRST INCIDENCE	464	435	652	461
STATISTICAL TESTS				
POLY 3	P=0.263N	P=0.486N	P=0.386N	P=0.316N
POLY 1.5	P=0.241N	P=0.489N	P=0.402N	P=0.290N
POLY 6	P=0.292N	P=0.488N	P=0.371N	P=0.354N
COCH-ARM / FISHERS	P=0.187N	P=0.500N	P=0.408N	P=0.235N
MAX-ISO-POLY-3	P=0.400N	P=0.393N	P=0.301N	P=0.244N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Thymus **Atrophy**				
LESION RATES				
OVERALL (a)	48/50 (96%)	46/47 (98%)	47/49 (96%)	46/50 (92%)
POLY-3 RATE (b)	48/49.31	46/46.65	47/47.82	46/48.60
POLY-3 PERCENT (g)	97.4%	98.6%	98.3%	94.7%
TERMINAL (d)	30/30 (100%)	28/28 (100%)	37/37 (100%)	22/23 (96%)
FIRST INCIDENCE	398	435	533	259
STATISTICAL TESTS				
POLY 3	P=0.230N	P=0.633	P=0.667	P=0.429N
POLY 1.5	P=0.268N	P=0.579	P=0.596	P=0.451N
POLY 6	P=0.181N	P=0.727	P=0.774	P=0.403N
COCH-ARM / FISHERS	P=0.171N	P=0.523	P=0.684N	P=0.339N
MAX-ISO-POLY-3	P=0.210N	P=0.304	P=0.361	P=0.231N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Thyroid Gland: C-Cell Hyperplasia				
LESION RATES				
OVERALL (a)	14/50 (28%)	14/50 (28%)	14/50 (28%)	14/50 (28%)
POLY-3 RATE (b)	14/43.22	14/45.14	14/46.03	14/40.15
POLY-3 PERCENT (g)	32.4%	31%	30.4%	34.9%
TERMINAL (d)	12/30 (40%)	10/30 (33%)	12/37 (32%)	11/23 (48%)
FIRST INCIDENCE	559	527	652	636
STATISTICAL TESTS				
POLY 3	P=0.438	P=0.536N	P=0.511N	P=0.497
POLY 1.5	P=0.464	P=0.555N	P=0.551N	P=0.522
POLY 6	P=0.406	P=0.516N	P=0.465N	P=0.461
COCH-ARM / FISHERS	P=0.542	P=0.588N	P=0.588N	P=0.588N
MAX-ISO-POLY-3	P=0.580	P=0.444N	P=0.421N	P=0.406

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Urinary Bladder
Calculus Gross Observation

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Males		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Urinary Bladder: Transitional Epithelium
Hyperplasia Adenomatous

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.38	0/43.21	0/45.64	0/39.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/30 (0%)	0/37 (0%)	0/23 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Adrenal Cortex **Degeneration Cystic**				
LESION RATES				
OVERALL (a)	5/50 (10%)	6/50 (12%)	4/50 (8%)	4/50 (8%)
POLY-3 RATE (b)	5/45.51	6/40.05	4/42.46	4/39.58
POLY-3 PERCENT (g)	11%	15%	9.4%	10.1%
TERMINAL (d)	4/36 (11%)	4/27 (15%)	2/34 (6%)	2/24 (8%)
FIRST INCIDENCE	672	644	680	640
STATISTICAL TESTS				
POLY 3	P=0.430N	P=0.411	P=0.543N	P=0.587N
POLY 1.5	P=0.402N	P=0.435	P=0.539N	P=0.554N
POLY 6	P=0.466N	P=0.382	P=0.542N	P=0.629N
COCH-ARM / FISHERS	P=0.357N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.533N	P=0.303	P=0.406N	P=0.450N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Adrenal Cortex Hypertrophy				
LESION RATES				
OVERALL (a)	3/50 (6%)	6/50 (12%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	3/45.84	6/39.94	1/42.32	2/39.15
POLY-3 PERCENT (g)	6.5%	15%	2.4%	5.1%
TERMINAL (d)	2/36 (6%)	4/27 (15%)	0/34 (0%)	2/24 (8%)
FIRST INCIDENCE	561	670	680	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.268N	P=0.178	P=0.334N	P=0.571N
POLY 1.5	P=0.246N	P=0.195	P=0.330N	P=0.544N
POLY 6	P=0.296N	P=0.159	P=0.335N	P=0.608N
COCH-ARM / FISHERS	P=0.210N	P=0.243	P=0.309N	P=0.500N
MAX-ISO-POLY-3	P=0.205N	P=0.116	P=0.184N	P=0.396N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Adrenal Cortex **Necrosis**				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/46.02	0/39.63	0/42.13	2/39.32
POLY-3 PERCENT (g)	4.4%	0%	0%	5.1%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	1/24 (4%)
FIRST INCIDENCE	594	---	---	684
STATISTICAL TESTS				
POLY 3	P=0.498	P=0.272N	P=0.257N	P=0.636
POLY 1.5	P=0.501	P=0.261N	P=0.254N	P=0.659
POLY 6	P=0.495	P=0.286N	P=0.260N	P=0.604
COCH-ARM / FISHERS	P=0.500	P=0.247N	P=0.247N	P=0.691N
MAX-ISO-POLY-3	P=0.259	P=0.108N	P=0.095N	P=0.440

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Adrenal Cortex: Zona Fasciculata
Hyperplasia

LESION RATES

OVERALL (a)	11/50 (22%)	10/50 (20%)	7/50 (14%)	8/50 (16%)
POLY-3 RATE (b)	11/45.82	10/40.38	7/42.13	8/39.41
POLY-3 PERCENT (g)	24%	24.8%	16.6%	20.3%
TERMINAL (d)	9/36 (25%)	7/27 (26%)	7/34 (21%)	6/24 (25%)
FIRST INCIDENCE	650	586	728 (T)	688

STATISTICAL TESTS

POLY 3	P=0.316N	P=0.567	P=0.276N	P=0.441N
POLY 1.5	P=0.278N	P=0.595N	P=0.266N	P=0.386N
POLY 6	P=0.368N	P=0.525	P=0.283N	P=0.518N
COCH-ARM / FISHERS	P=0.228N	P=0.500N	P=0.218N	P=0.306N
MAX-ISO-POLY-3	P=0.426N	P=0.468	P=0.205N	P=0.350N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Adrenal Medulla **Hyperplasia**				
LESION RATES				
OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	2/45.30	3/39.63	3/42.43	1/39.15
POLY-3 PERCENT (g)	4.4%	7.6%	7.1%	2.6%
TERMINAL (d)	2/36 (6%)	3/27 (11%)	2/34 (6%)	1/24 (4%)
FIRST INCIDENCE	728 (T)	728 (T)	648	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.407N	P=0.439	P=0.470	P=0.551N
POLY 1.5	P=0.382N	P=0.456	P=0.473	P=0.531N
POLY 6	P=0.440N	P=0.418	P=0.473	P=0.577N
COCH-ARM / FISHERS	P=0.343N	P=0.500	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.389N	P=0.284	P=0.303	P=0.335N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Bone Marrow Hyperplasia				
LESION RATES				
OVERALL (a)	13/50 (26%)	18/50 (36%)	18/50 (36%)	18/50 (36%)
POLY-3 RATE (b)	13/46.97	18/44.42	18/43.47	18/44.31
POLY-3 PERCENT (g)	27.7%	40.5%	41.4%	40.6%
TERMINAL (d)	7/36 (19%)	7/27 (26%)	14/34 (41%)	6/24 (25%)
FIRST INCIDENCE	561	5	533	61
STATISTICAL TESTS				
POLY 3	P=0.149	P=0.139	P=0.123	P=0.136
POLY 1.5	P=0.177	P=0.158	P=0.134	P=0.161
POLY 6	P=0.116	P=0.120	P=0.116	P=0.107
COCH-ARM / FISHERS	P=0.216	P=0.194	P=0.194	P=0.194
MAX-ISO-POLY-3	P=0.152	P=0.101	P=0.091	P=0.100

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Bone: Femur				
Osteopetrosis				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/45.51	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	6.6%	0%	0%	0%
TERMINAL (d)	2/36 (6%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	672	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.039N*	P=0.145N	P=0.133N	P=0.148N
POLY 1.5	P=0.041N*	P=0.137N	P=0.131N	P=0.136N
POLY 6	P=0.037N*	P=0.156N	P=0.134N	P=0.166N
COCH-ARM / FISHERS	P=0.047N*	P=0.121N	P=0.121N	P=0.121N
MAX-ISO-POLY-3	P=0.023N*	P=0.061N	P=0.050N*	P=0.063N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Brain **Necrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Eye: Cornea **Fibrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	3/50 (6%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/45.30	3/39.63	1/42.13	2/39.15
POLY-3 PERCENT (g)	0%	7.6%	2.4%	5.1%
TERMINAL (d)	0/36 (0%)	3/27 (11%)	1/34 (3%)	2/24 (8%)
FIRST INCIDENCE	---	728 (T)	728 (T)	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.271	P=0.096	P=0.486	P=0.206
POLY 1.5	P=0.295	P=0.102	P=0.487	P=0.218
POLY 6	P=0.243	P=0.089	P=0.485	P=0.191
COCH-ARM / FISHERS	P=0.337	P=0.121	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.190	P=0.037*	P=0.158	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Eye: Cornea Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/45.30	1/39.72	0/42.13	2/39.15
POLY-3 PERCENT (g)	0%	2.5%	0%	5.1%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	2/24 (8%)
FIRST INCIDENCE	---	706	---	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.121	P=0.474	(e)	P=0.206
POLY 1.5	P=0.127	P=0.481	(e)	P=0.218
POLY 6	P=0.113	P=0.465	(e)	P=0.191
COCH-ARM / FISHERS	P=0.140	P=0.500	(e)	P=0.247
MAX-ISO-POLY-3	P=0.077	P=0.158	(e)	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Eye: Lens
Cataract

LESION RATES

OVERALL (a)	3/50 (6%)	3/50 (6%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	3/45.30	3/40.44	4/42.13	2/40.30
POLY-3 PERCENT (g)	6.6%	7.4%	9.5%	5%
TERMINAL (d)	3/36 (8%)	1/27 (4%)	4/34 (12%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	476	728 (T)	541

STATISTICAL TESTS

POLY 3	P=0.473N	P=0.609	P=0.460	P=0.553N
POLY 1.5	P=0.452N	P=0.623	P=0.466	P=0.533N
POLY 6	P=0.502N	P=0.592	P=0.460	P=0.579N
COCH-ARM / FISHERS	P=0.420N	P=0.661N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.500N	P=0.444	P=0.318	P=0.378N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Eye: Retina Degeneration				
LESION RATES				
OVERALL (a)	3/50 (6%)	4/50 (8%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/45.30	4/40.83	2/42.13	1/39.74
POLY-3 PERCENT (g)	6.6%	9.8%	4.8%	2.5%
TERMINAL (d)	3/36 (8%)	2/27 (7%)	2/34 (6%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	476	728 (T)	541
STATISTICAL TESTS				
POLY 3	P=0.199N	P=0.443	P=0.533N	P=0.353N
POLY 1.5	P=0.185N	P=0.457	P=0.529N	P=0.335N
POLY 6	P=0.219N	P=0.426	P=0.533N	P=0.379N
COCH-ARM / FISHERS	P=0.162N	P=0.500	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.246N	P=0.306	P=0.358N	P=0.203N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Heart **Cardiomyopathy**				
LESION RATES				
OVERALL (a)	47/50 (94%)	43/50 (86%)	48/50 (96%)	46/50 (92%)
POLY-3 RATE (b)	47/49.74	43/45.99	48/48.32	46/47.93
POLY-3 PERCENT (g)	94.5%	93.5%	99.3%	96%
TERMINAL (d)	34/36 (94%)	26/27 (96%)	34/34 (100%)	23/24 (96%)
FIRST INCIDENCE	397	476	119	439
STATISTICAL TESTS				
POLY 3	P=0.338	P=0.597N	P=0.195	P=0.555
POLY 1.5	P=0.382	P=0.498N	P=0.234	P=0.605
POLY 6	P=0.305	P=0.688	P=0.173	P=0.512
COCH-ARM / FISHERS	P=0.500	P=0.159N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.262	P=0.415N	P=0.072	P=0.360

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Heart: Atrium
Thrombosis

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/45.30	1/40.31	0/42.13	1/39.34
POLY-3 PERCENT (g)	0%	2.5%	0%	2.5%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	500	---	677

STATISTICAL TESTS

POLY 3	P=0.366	P=0.477	(e)	P=0.472
POLY 1.5	P=0.380	P=0.483	(e)	P=0.483
POLY 6	P=0.349	P=0.469	(e)	P=0.458
COCH-ARM / FISHERS	P=0.405	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.255	P=0.158	(e)	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Intestine Large, Colon
Parasite Metazoan

LESION RATES

OVERALL (a)	5/50 (10%)	9/50 (18%)	7/50 (14%)	4/50 (8%)
POLY-3 RATE (b)	5/45.30	9/39.74	7/42.43	4/39.54
POLY-3 PERCENT (g)	11%	22.7%	16.5%	10.1%
TERMINAL (d)	5/36 (14%)	8/27 (30%)	6/34 (18%)	3/24 (13%)
FIRST INCIDENCE	728 (T)	701	646	618

STATISTICAL TESTS

POLY 3	P=0.395N	P=0.125	P=0.333	P=0.585N
POLY 1.5	P=0.355N	P=0.143	P=0.338	P=0.553N
POLY 6	P=0.448N	P=0.105	P=0.336	P=0.626N
COCH-ARM / FISHERS	P=0.294N	P=0.194	P=0.380	P=0.500N
MAX-ISO-POLY-3	P=0.355N	P=0.087	P=0.237	P=0.448N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Islets, Pancreatic **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	1/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	2.4%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	1/34 (3%)	0/24 (0%)
FIRST INCIDENCE	---	---	728 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.645	(e)	P=0.486	(e)
POLY 1.5	P=0.668	(e)	P=0.487	(e)
POLY 6	P=0.610	(e)	P=0.485	(e)
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.400	(e)	P=0.158	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Kidney
Accumulation, Hyaline Droplet

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	2.2%	0%	0%	0%
TERMINAL (d)	1/36 (3%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.284N	P=0.527N	P=0.514N	P=0.529N
POLY 1.5	P=0.292N	P=0.519N	P=0.513N	P=0.518N
POLY 6	P=0.271N	P=0.536N	P=0.514N	P=0.544N
COCH-ARM / FISHERS	P=0.306N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.176N	P=0.191N	P=0.176N	P=0.194N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Kidney **Mineralization**				
LESION RATES				
OVERALL (a)	39/50 (78%)	37/50 (74%)	41/50 (82%)	46/50 (92%)
POLY-3 RATE (b)	39/48.58	37/47.82	41/48.01	46/49.30
POLY-3 PERCENT (g)	80.3%	77.4%	85.4%	93.3%
TERMINAL (d)	30/36 (83%)	20/27 (74%)	28/34 (82%)	22/24 (92%)
FIRST INCIDENCE	397	5	119	61
STATISTICAL TESTS				
POLY 3	P=0.018*	P=0.459N	P=0.341	P=0.045*
POLY 1.5	P=0.017*	P=0.438N	P=0.325	P=0.043*
POLY 6	P=0.024*	P=0.483N	P=0.387	P=0.053
COCH-ARM / FISHERS	P=0.020*	P=0.408N	P=0.402	P=0.045*
MAX-ISO-POLY-3	P=0.028*	P=0.359N	P=0.248	P=0.023*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Kidney **Nephropathy**				
LESION RATES				
OVERALL (a)	42/50 (84%)	36/50 (72%)	43/50 (86%)	39/50 (78%)
POLY-3 RATE (b)	42/48.46	36/43.22	43/45.46	39/45.88
POLY-3 PERCENT (g)	86.7%	83.3%	94.6%	85%
TERMINAL (d)	34/36 (94%)	26/27 (96%)	33/34 (97%)	24/24 (100%)
FIRST INCIDENCE	397	500	497	61
STATISTICAL TESTS				
POLY 3	P=0.551	P=0.430N	P=0.146	P=0.528N
POLY 1.5	P=0.488N	P=0.323N	P=0.184	P=0.417N
POLY 6	P=0.413	P=0.581N	P=0.152	P=0.602
COCH-ARM / FISHERS	P=0.452N	P=0.114N	P=0.500	P=0.306N
MAX-ISO-POLY-3	P=0.355	P=0.318N	P=0.081	P=0.398N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Kidney: Pelvis **Inflammation**				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	3/45.30	0/39.63	0/42.13	1/39.93
POLY-3 PERCENT (g)	6.6%	0%	0%	2.5%
TERMINAL (d)	3/36 (8%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	---	---	439
STATISTICAL TESTS				
POLY 3	P=0.230N	P=0.144N	P=0.132N	P=0.352N
POLY 1.5	P=0.235N	P=0.137N	P=0.131N	P=0.334N
POLY 6	P=0.222N	P=0.154N	P=0.132N	P=0.378N
COCH-ARM / FISHERS	P=0.247N	P=0.121N	P=0.121N	P=0.309N
MAX-ISO-POLY-3	P=0.074N	P=0.060N	P=0.049N*	P=0.201N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Larynx **Foreign Body**				
LESION RATES				
OVERALL (a)	1/1 (100%)	0/0 (0%)	0/0 (0%)	2/2 (100%)
POLY-3 RATE (b)	1/1.00	0/0.00	0/0.00	2/2.00
POLY-3 PERCENT (g)	100%	0%	0%	100%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	397	---	---	572
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Angiectasis**				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/45.30	1/39.63	0/42.13	2/39.15
POLY-3 PERCENT (g)	2.2%	2.5%	0%	5.1%
TERMINAL (d)	1/36 (3%)	1/27 (4%)	0/34 (0%)	2/24 (8%)
FIRST INCIDENCE	728 (T)	728 (T)	---	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.342	P=0.730	P=0.514N	P=0.449
POLY 1.5	P=0.352	P=0.739	P=0.513N	P=0.469
POLY 6	P=0.331	P=0.719	P=0.514N	P=0.423
COCH-ARM / FISHERS	P=0.366	P=0.753N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.261	P=0.464	P=0.176N	P=0.254

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Basophilic Focus**				
LESION RATES				
OVERALL (a)	46/50 (92%)	38/50 (76%)	46/50 (92%)	45/50 (90%)
POLY-3 RATE (b)	46/49.07	38/43.20	46/46.45	45/47.26
POLY-3 PERCENT (g)	93.7%	88%	99%	95.2%
TERMINAL (d)	35/36 (97%)	26/27 (96%)	34/34 (100%)	24/24 (100%)
FIRST INCIDENCE	397	598	459	461
STATISTICAL TESTS				
POLY 3	P=0.236	P=0.244N	P=0.170	P=0.558
POLY 1.5	P=0.255	P=0.144N	P=0.218	P=0.600
POLY 6	P=0.221	P=0.392N	P=0.174	P=0.521
COCH-ARM / FISHERS	P=0.345	P=0.027N*	P=0.643N	P=0.500N
MAX-ISO-POLY-3	P=0.103	P=0.147N	P=0.061	P=0.360

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Clear Cell Focus**				
LESION RATES				
OVERALL (a)	6/50 (12%)	3/50 (6%)	8/50 (16%)	6/50 (12%)
POLY-3 RATE (b)	6/45.30	3/39.63	8/42.68	6/39.84
POLY-3 PERCENT (g)	13.2%	7.6%	18.8%	15.1%
TERMINAL (d)	6/36 (17%)	3/27 (11%)	6/34 (18%)	3/24 (13%)
FIRST INCIDENCE	728 (T)	728 (T)	646	590
STATISTICAL TESTS				
POLY 3	P=0.329	P=0.312N	P=0.340	P=0.528
POLY 1.5	P=0.357	P=0.292N	P=0.343	P=0.563
POLY 6	P=0.294	P=0.337N	P=0.347	P=0.483
COCH-ARM / FISHERS	P=0.397	P=0.243N	P=0.387	P=0.620N
MAX-ISO-POLY-3	P=0.339	P=0.215N	P=0.248	P=0.409

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Degeneration Cystic**				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	2.2%	0%	0%	0%
TERMINAL (d)	1/36 (3%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.284N	P=0.527N	P=0.514N	P=0.529N
POLY 1.5	P=0.292N	P=0.519N	P=0.513N	P=0.518N
POLY 6	P=0.271N	P=0.536N	P=0.514N	P=0.544N
COCH-ARM / FISHERS	P=0.306N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.176N	P=0.191N	P=0.176N	P=0.194N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Eosinophilic Focus**				
LESION RATES				
OVERALL (a)	16/50 (32%)	10/50 (20%)	12/50 (24%)	13/50 (26%)
POLY-3 RATE (b)	16/46.30	10/40.40	12/43.46	13/40.77
POLY-3 PERCENT (g)	34.6%	24.8%	27.6%	31.9%
TERMINAL (d)	13/36 (36%)	7/27 (26%)	8/34 (24%)	9/24 (38%)
FIRST INCIDENCE	592	614	586	530
STATISTICAL TESTS				
POLY 3	P=0.492N	P=0.223N	P=0.315N	P=0.486N
POLY 1.5	P=0.455N	P=0.192N	P=0.311N	P=0.425N
POLY 6	P=0.541N	P=0.264N	P=0.305N	P=0.568N
COCH-ARM / FISHERS	P=0.403N	P=0.127N	P=0.252N	P=0.330N
MAX-ISO-POLY-3	P=0.426N	P=0.175N	P=0.246N	P=0.399N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Liver
Fatty Change Diffuse

LESION RATES

OVERALL (a)	5/50 (10%)	4/50 (8%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	5/46.26	4/41.99	4/42.80	5/40.50
POLY-3 PERCENT (g)	10.8%	9.5%	9.4%	12.4%
TERMINAL (d)	2/36 (6%)	0/27 (0%)	3/34 (9%)	1/24 (4%)
FIRST INCIDENCE	594	500	504	600

STATISTICAL TESTS

POLY 3	P=0.462	P=0.560N	P=0.549N	P=0.545
POLY 1.5	P=0.491	P=0.546N	P=0.541N	P=0.577
POLY 6	P=0.428	P=0.580N	P=0.554N	P=0.503
COCH-ARM / FISHERS	P=0.533	P=0.500N	P=0.500N	P=0.630N
MAX-ISO-POLY-3	P=0.575	P=0.423N	P=0.411N	P=0.415

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Fatty Change Focal**				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/45.50	2/39.74	0/42.13	0/39.15
POLY-3 PERCENT (g)	2.2%	5%	0%	0%
TERMINAL (d)	0/36 (0%)	1/27 (4%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	677	701	---	---
STATISTICAL TESTS				
POLY 3	P=0.211N	P=0.453	P=0.515N	P=0.530N
POLY 1.5	P=0.204N	P=0.466	P=0.513N	P=0.518N
POLY 6	P=0.220N	P=0.437	P=0.516N	P=0.546N
COCH-ARM / FISHERS	P=0.188N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.206N	P=0.256	P=0.177N	P=0.195N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Liver
Hematopoietic Cell Proliferation

LESION RATES

OVERALL (a)	6/50 (12%)	6/50 (12%)	7/50 (14%)	4/50 (8%)
POLY-3 RATE (b)	6/45.59	6/39.96	7/42.74	4/39.64
POLY-3 PERCENT (g)	13.2%	15%	16.4%	10.1%
TERMINAL (d)	5/36 (14%)	5/27 (19%)	6/34 (18%)	2/24 (8%)
FIRST INCIDENCE	650	639	533	618

STATISTICAL TESTS

POLY 3	P=0.397N	P=0.526	P=0.450	P=0.460N
POLY 1.5	P=0.362N	P=0.553	P=0.455	P=0.425N
POLY 6	P=0.443N	P=0.493	P=0.451	P=0.506N
COCH-ARM / FISHERS	P=0.313N	P=0.620N	P=0.500	P=0.370N
MAX-ISO-POLY-3	P=0.445N	P=0.407	P=0.340	P=0.341N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Hepatodiaphragmatic Nodule**				
LESION RATES				
OVERALL (a)	4/50 (8%)	4/50 (8%)	2/50 (4%)	5/50 (10%)
POLY-3 RATE (b)	4/46.06	4/40.04	2/42.38	5/40.77
POLY-3 PERCENT (g)	8.7%	10%	4.7%	12.3%
TERMINAL (d)	2/36 (6%)	2/27 (7%)	1/34 (3%)	1/24 (4%)
FIRST INCIDENCE	561	639	663	439
STATISTICAL TESTS				
POLY 3	P=0.397	P=0.565	P=0.376N	P=0.424
POLY 1.5	P=0.417	P=0.587	P=0.370N	P=0.453
POLY 6	P=0.372	P=0.537	P=0.379N	P=0.385
COCH-ARM / FISHERS	P=0.446	P=0.643N	P=0.339N	P=0.500
MAX-ISO-POLY-3	P=0.393	P=0.422	P=0.240N	P=0.304

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver Inflammation				
LESION RATES				
OVERALL (a)	43/50 (86%)	38/50 (76%)	43/50 (86%)	45/50 (90%)
POLY-3 RATE (b)	43/49.07	38/45.84	43/47.69	45/47.87
POLY-3 PERCENT (g)	87.6%	82.9%	90.2%	94%
TERMINAL (d)	32/36 (89%)	23/27 (85%)	30/34 (88%)	24/24 (100%)
FIRST INCIDENCE	397	322	275	439
STATISTICAL TESTS				
POLY 3	P=0.104	P=0.353N	P=0.470	P=0.215
POLY 1.5	P=0.114	P=0.316N	P=0.449	P=0.245
POLY 6	P=0.089	P=0.395N	P=0.516	P=0.171
COCH-ARM / FISHERS	P=0.169	P=0.154N	P=0.613N	P=0.380
MAX-ISO-POLY-3	P=0.122	P=0.255N	P=0.344	P=0.125

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Mixed Cell Focus**				
LESION RATES				
OVERALL (a)	5/50 (10%)	3/50 (6%)	5/50 (10%)	4/50 (8%)
POLY-3 RATE (b)	5/45.99	3/39.71	5/42.39	4/39.15
POLY-3 PERCENT (g)	10.9%	7.6%	11.8%	10.2%
TERMINAL (d)	3/36 (8%)	2/27 (7%)	3/34 (9%)	4/24 (17%)
FIRST INCIDENCE	629	709	680	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.540	P=0.439N	P=0.578	P=0.600N
POLY 1.5	P=0.557N	P=0.414N	P=0.587	P=0.561N
POLY 6	P=0.492	P=0.472N	P=0.575	P=0.622
COCH-ARM / FISHERS	P=0.517N	P=0.357N	P=0.630N	P=0.500N
MAX-ISO-POLY-3	P=0.630	P=0.313N	P=0.447	P=0.463N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Necrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/45.30	2/40.49	1/42.13	1/39.15
POLY-3 PERCENT (g)	0%	4.9%	2.4%	2.6%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	1/34 (3%)	1/24 (4%)
FIRST INCIDENCE	---	500	728 (T)	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.432	P=0.213	P=0.486	P=0.471
POLY 1.5	P=0.458	P=0.219	P=0.487	P=0.482
POLY 6	P=0.398	P=0.206	P=0.485	P=0.456
COCH-ARM / FISHERS	P=0.500	P=0.247	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.290	P=0.075	P=0.158	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver **Pigmentation Hemosiderin**				
LESION RATES				
OVERALL (a)	2/50 (4%)	3/50 (6%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/45.64	3/40.33	0/42.13	2/39.47
POLY-3 PERCENT (g)	4.4%	7.4%	0%	5.1%
TERMINAL (d)	1/36 (3%)	1/27 (4%)	0/34 (0%)	1/24 (4%)
FIRST INCIDENCE	635	533	---	639
STATISTICAL TESTS				
POLY 3	P=0.510N	P=0.444	P=0.255N	P=0.641
POLY 1.5	P=0.498N	P=0.459	P=0.253N	P=0.661
POLY 6	P=0.522N	P=0.425	P=0.257N	P=0.612
COCH-ARM / FISHERS	P=0.474N	P=0.500	P=0.247N	P=0.691N
MAX-ISO-POLY-3	P=0.379N	P=0.287	P=0.093N	P=0.444

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver: Bile Duct Hyperplasia				
LESION RATES				
OVERALL (a)	19/50 (38%)	19/50 (38%)	17/50 (34%)	9/50 (18%)
POLY-3 RATE (b)	19/45.85	19/41.37	17/43.96	9/40.56
POLY-3 PERCENT (g)	41.4%	45.9%	38.7%	22.2%
TERMINAL (d)	17/36 (47%)	14/27 (52%)	13/34 (38%)	6/24 (25%)
FIRST INCIDENCE	635	500	504	461
STATISTICAL TESTS				
POLY 3	P=0.023N*	P=0.417	P=0.479N	P=0.043N*
POLY 1.5	P=0.017N*	P=0.458	P=0.484N	P=0.033N*
POLY 6	P=0.035N*	P=0.370	P=0.458N	P=0.063N
COCH-ARM / FISHERS	P=0.012N*	P=0.582N	P=0.418N	P=0.022N*
MAX-ISO-POLY-3	P=0.035N*	P=0.341	P=0.394N	P=0.032N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver: Centrilobular Degeneration				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	1/40.31	2/42.21	0/39.15
POLY-3 PERCENT (g)	0%	2.5%	4.7%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	1/34 (3%)	0/24 (0%)
FIRST INCIDENCE	---	500	709	---
STATISTICAL TESTS				
POLY 3	P=0.617	P=0.477	P=0.222	(e)
POLY 1.5	P=0.648	P=0.483	P=0.224	(e)
POLY 6	P=0.573	P=0.469	P=0.222	(e)
COCH-ARM / FISHERS	P=0.616N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.345	P=0.158	P=0.076	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Liver: Oval Cell Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	2/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	4.8%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	2/34 (6%)	0/24 (0%)
FIRST INCIDENCE	---	---	728 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.532	(e)	P=0.221	(e)
POLY 1.5	P=0.561	(e)	P=0.223	(e)
POLY 6	P=0.489	(e)	P=0.221	(e)
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.266	(e)	P=0.076	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung Congestion				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/45.30	0/39.63	2/43.76	1/39.76
POLY-3 PERCENT (g)	0%	0%	4.6%	2.5%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	275	532
STATISTICAL TESTS				
POLY 3	P=0.210	(e)	P=0.229	P=0.474
POLY 1.5	P=0.225	(e)	P=0.229	P=0.484
POLY 6	P=0.189	(e)	P=0.231	P=0.461
COCH-ARM / FISHERS	P=0.246	(e)	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.191	(e)	P=0.076	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung **Fibrosis**				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/45.64	0/39.63	0/42.13	1/39.15
POLY-3 PERCENT (g)	2.2%	0%	0%	2.6%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	1/24 (4%)
FIRST INCIDENCE	635	---	---	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.587	P=0.528N	P=0.516N	P=0.725
POLY 1.5	P=0.592	P=0.520N	P=0.513N	P=0.739
POLY 6	P=0.581	P=0.538N	P=0.517N	P=0.705
COCH-ARM / FISHERS	P=0.595	P=0.500N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.394	P=0.192N	P=0.178N	P=0.459

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung **Inflammation**				
LESION RATES				
OVERALL (a)	4/50 (8%)	7/50 (14%)	6/50 (12%)	5/50 (10%)
POLY-3 RATE (b)	4/45.76	7/40.54	6/43.05	5/39.66
POLY-3 PERCENT (g)	8.7%	17.3%	13.9%	12.6%
TERMINAL (d)	3/36 (8%)	3/27 (11%)	4/34 (12%)	4/24 (17%)
FIRST INCIDENCE	594	618	533	572
STATISTICAL TESTS				
POLY 3	P=0.421	P=0.195	P=0.331	P=0.411
POLY 1.5	P=0.464	P=0.211	P=0.334	P=0.445
POLY 6	P=0.366	P=0.178	P=0.334	P=0.366
COCH-ARM / FISHERS	P=0.530	P=0.262	P=0.370	P=0.500
MAX-ISO-POLY-3	P=0.366	P=0.132	P=0.228	P=0.295

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lung **Thrombosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Lung: Alveolar Epithelium
Hyperplasia

LESION RATES

OVERALL (a)	10/50 (20%)	10/50 (20%)	6/50 (12%)	5/50 (10%)
POLY-3 RATE (b)	10/45.30	10/40.40	6/42.43	5/39.26
POLY-3 PERCENT (g)	22.1%	24.8%	14.1%	12.7%
TERMINAL (d)	10/36 (28%)	8/27 (30%)	5/34 (15%)	4/24 (17%)
FIRST INCIDENCE	728 (T)	544	646	701

STATISTICAL TESTS

POLY 3	P=0.104N	P=0.485	P=0.247N	P=0.201N
POLY 1.5	P=0.089N	P=0.515	P=0.244N	P=0.172N
POLY 6	P=0.126N	P=0.451	P=0.241N	P=0.247N
COCH-ARM / FISHERS	P=0.069N	P=0.598N	P=0.207N	P=0.131N
MAX-ISO-POLY-3	P=0.165N	P=0.389	P=0.176N	P=0.146N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Lung: Alveolar Epithelium Metaplasia

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/45.64	2/39.95	1/42.44	1/39.15
POLY-3 PERCENT (g)	2.2%	5%	2.4%	2.6%
TERMINAL (d)	0/36 (0%)	1/27 (4%)	0/34 (0%)	1/24 (4%)
FIRST INCIDENCE	635	640	643	728 (T)

STATISTICAL TESTS

POLY 3	P=0.574N	P=0.454	P=0.744	P=0.725
POLY 1.5	P=0.558N	P=0.467	P=0.746	P=0.739
POLY 6	P=0.593N	P=0.438	P=0.744	P=0.705
COCH-ARM / FISHERS	P=0.531N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.612	P=0.256	P=0.479	P=0.459

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Lung: Alveolus
Infiltration Cellular Histiocyte

LESION RATES

OVERALL (a)	14/50 (28%)	13/50 (26%)	15/50 (30%)	9/50 (18%)
POLY-3 RATE (b)	14/45.46	13/40.67	15/42.79	9/40.28
POLY-3 PERCENT (g)	30.8%	32%	35.1%	22.3%
TERMINAL (d)	13/36 (36%)	9/27 (33%)	13/34 (38%)	5/24 (21%)
FIRST INCIDENCE	688	618	586	552

STATISTICAL TESTS

POLY 3	P=0.233N	P=0.546	P=0.421	P=0.261N
POLY 1.5	P=0.199N	P=0.578	P=0.427	P=0.225N
POLY 6	P=0.282N	P=0.512	P=0.430	P=0.312N
COCH-ARM / FISHERS	P=0.155N	P=0.500N	P=0.500	P=0.171N
MAX-ISO-POLY-3	P=0.261N	P=0.454	P=0.339	P=0.201N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node, Mesenteric **Atrophy**				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	2/45.30	0/39.63	3/42.13	1/39.93
POLY-3 PERCENT (g)	4.4%	0%	7.1%	2.5%
TERMINAL (d)	2/36 (6%)	0/27 (0%)	3/34 (9%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	---	728 (T)	439
STATISTICAL TESTS				
POLY 3	P=0.579N	P=0.268N	P=0.467	P=0.544N
POLY 1.5	P=0.566N	P=0.259N	P=0.471	P=0.527N
POLY 6	P=0.597N	P=0.279N	P=0.467	P=0.567N
COCH-ARM / FISHERS	P=0.556N	P=0.247N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.446	P=0.105N	P=0.301	P=0.328N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node, Mesenteric				
Ectasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node, Mesenteric **Hyperplasia Lymphoid**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	2/40.40
POLY-3 PERCENT (g)	0%	0%	0%	5%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	461
STATISTICAL TESTS				
POLY 3	P=0.043*	(e)	(e)	P=0.212
POLY 1.5	P=0.044*	(e)	(e)	P=0.222
POLY 6	P=0.042*	(e)	(e)	P=0.200
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node: Mediastinal **Ectasia**				
LESION RATES				
OVERALL (a)	0/1 (0%)	0/5 (0%)	0/4 (0%)	0/4 (0%)
POLY-3 RATE (b)	0/0.82	0/4.39	0/3.08	0/3.52
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/2 (0%)	0/0 (0%)	0/2 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node: Mediastinal **Hyperplasia Lymphoid**				
LESION RATES				
OVERALL (a)	0/1 (0%)	2/5 (40%)	0/4 (0%)	1/4 (25%)
POLY-3 RATE (b)	0/0.82	2/4.61	0/3.08	1/3.52
POLY-3 PERCENT (g)	0%	43.4%	0%	28.4%
TERMINAL (d)	0/0 (0%)	1/2 (50%)	0/0 (0%)	1/2 (50%)
FIRST INCIDENCE	---	670	---	728 (T)
STATISTICAL TESTS				
POLY 3	P=0.632N	P=0.662	(e)	P=0.765
POLY 1.5	P=0.636N	P=0.646	(e)	P=0.757
POLY 6	P=0.622N	P=0.694	(e)	P=0.782
COCH-ARM / FISHERS	P=0.649N	P=0.667	(e)	P=0.800
MAX-ISO-POLY-3	P=0.554	P=0.316	(e)	P=0.366

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Lymph Node: Mediastinal
Infiltration Cellular Plasma Cell

LESION RATES

OVERALL (a)	0/1 (0%)	0/5 (0%)	1/4 (25%)	1/4 (25%)
POLY-3 RATE (b)	0/0.82	0/4.39	1/3.27	1/3.52
POLY-3 PERCENT (g)	0%	0%	30.6%	28.4%
TERMINAL (d)	0/0 (0%)	0/2 (0%)	0/0 (0%)	1/2 (50%)
FIRST INCIDENCE	---	---	680	728 (T)

STATISTICAL TESTS

POLY 3	P=0.330	(e)	P=0.762	P=0.765
POLY 1.5	P=0.329	(e)	P=0.755	P=0.757
POLY 6	P=0.336	(e)	P=0.781	P=0.782
COCH-ARM / FISHERS	P=0.312	(e)	P=0.800	P=0.800
MAX-ISO-POLY-3	P=0.518	(e)	P=0.353	P=0.366

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Lymph Node: Pancreatic				
Ectasia				
LESION RATES				
OVERALL (a)	0/1 (0%)	0/5 (0%)	0/4 (0%)	0/4 (0%)
POLY-3 RATE (b)	0/0.82	0/4.39	0/3.08	0/3.52
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/2 (0%)	0/0 (0%)	0/2 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Mammary Gland Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	2/39.96	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	5%	0%	0%
TERMINAL (d)	0/36 (0%)	1/27 (4%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	639	---	---
STATISTICAL TESTS				
POLY 3	P=0.448N	P=0.210	(e)	(e)
POLY 1.5	P=0.435N	P=0.217	(e)	(e)
POLY 6	P=0.463N	P=0.202	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.284N	P=0.075	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Mesentery: Fat Necrosis				
LESION RATES				
OVERALL (a)	9/9 (100%)	8/8 (100%)	6/6 (100%)	6/6 (100%)
POLY-3 RATE (b)	9/9.00	8/8.00	6/6.00	6/6.00
POLY-3 PERCENT (g)	100%	100%	100%	100%
TERMINAL (d)	7/7 (100%)	5/5 (100%)	4/4 (100%)	4/4 (100%)
FIRST INCIDENCE	635	639	691	612
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Nose
Foreign Body

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/45.30	1/39.63	1/42.13	2/39.15
POLY-3 PERCENT (g)	2.2%	2.5%	2.4%	5.1%
TERMINAL (d)	1/36 (3%)	1/27 (4%)	1/34 (3%)	2/24 (8%)
FIRST INCIDENCE	728 (T)	728 (T)	728 (T)	728 (T)

STATISTICAL TESTS

POLY 3	P=0.315	P=0.730	P=0.744	P=0.449
POLY 1.5	P=0.330	P=0.739	P=0.746	P=0.469
POLY 6	P=0.296	P=0.719	P=0.744	P=0.423
COCH-ARM / FISHERS	P=0.351	P=0.753N	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.379	P=0.464	P=0.479	P=0.254

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Nose: Olfactory Epithelium Inflammation				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	1/45.30	0/39.63	0/42.13	4/40.61
POLY-3 PERCENT (g)	2.2%	0%	0%	9.9%
TERMINAL (d)	1/36 (3%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	---	---	439
STATISTICAL TESTS				
POLY 3	P=0.026*	P=0.527N	P=0.514N	P=0.147
POLY 1.5	P=0.026*	P=0.519N	P=0.513N	P=0.158
POLY 6	P=0.025*	P=0.536N	P=0.514N	P=0.133
COCH-ARM / FISHERS	P=0.028*	P=0.500N	P=0.500N	P=0.181
MAX-ISO-POLY-3	P=0.012*	P=0.191N	P=0.176N	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Nose: Respiratory Epithelium
Inflammation

LESION RATES

OVERALL (a)	3/50 (6%)	2/50 (4%)	1/50 (2%)	10/50 (20%)
POLY-3 RATE (b)	3/45.30	2/40.08	1/42.13	10/40.67
POLY-3 PERCENT (g)	6.6%	5%	2.4%	24.6%
TERMINAL (d)	3/36 (8%)	1/27 (4%)	1/34 (3%)	5/24 (21%)
FIRST INCIDENCE	728 (T)	598	728 (T)	439

STATISTICAL TESTS

POLY 3	P=0.003**	P=0.556N	P=0.332N	P=0.019*
POLY 1.5	P=0.003**	P=0.541N	P=0.328N	P=0.024*
POLY 6	P=0.002**	P=0.573N	P=0.331N	P=0.014*
COCH-ARM / FISHERS	P=0.004**	P=0.500N	P=0.309N	P=0.036*
MAX-ISO-POLY-3	P=0.002**	P=0.381N	P=0.181N	P=0.012*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Ovary Cyst				
LESION RATES				
OVERALL (a)	6/50 (12%)	5/50 (10%)	9/50 (18%)	7/50 (14%)
POLY-3 RATE (b)	6/45.77	5/40.46	9/43.04	7/40.83
POLY-3 PERCENT (g)	13.1%	12.4%	20.9%	17.2%
TERMINAL (d)	4/36 (11%)	3/27 (11%)	7/34 (21%)	3/24 (13%)
FIRST INCIDENCE	650	533	533	532
STATISTICAL TESTS				
POLY 3	P=0.279	P=0.586N	P=0.243	P=0.412
POLY 1.5	P=0.308	P=0.563N	P=0.247	P=0.444
POLY 6	P=0.243	P=0.615N	P=0.244	P=0.369
COCH-ARM / FISHERS	P=0.350	P=0.500N	P=0.288	P=0.500
MAX-ISO-POLY-3	P=0.359	P=0.460N	P=0.171	P=0.310

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Pancreas **Atrophy**				
LESION RATES				
OVERALL (a)	16/50 (32%)	11/50 (22%)	12/50 (24%)	12/50 (24%)
POLY-3 RATE (b)	16/46.21	11/40.18	12/44.00	12/41.44
POLY-3 PERCENT (g)	34.6%	27.4%	27.3%	29%
TERMINAL (d)	13/36 (36%)	9/27 (33%)	8/34 (24%)	5/24 (21%)
FIRST INCIDENCE	561	598	459	532
STATISTICAL TESTS				
POLY 3	P=0.342N	P=0.311N	P=0.299N	P=0.367N
POLY 1.5	P=0.318N	P=0.271N	P=0.300N	P=0.324N
POLY 6	P=0.371N	P=0.365N	P=0.289N	P=0.423N
COCH-ARM / FISHERS	P=0.282N	P=0.184N	P=0.252N	P=0.252N
MAX-ISO-POLY-3	P=0.408N	P=0.248N	P=0.231N	P=0.294N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Pancreas **Inflammation**				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/45.51	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	2.2%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	672	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.283N	P=0.527N	P=0.515N	P=0.530N
POLY 1.5	P=0.292N	P=0.520N	P=0.513N	P=0.518N
POLY 6	P=0.270N	P=0.537N	P=0.516N	P=0.546N
COCH-ARM / FISHERS	P=0.306N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.178N	P=0.192N	P=0.177N	P=0.195N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Pancreas: Acinus **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Parathyroid Gland Hyperplasia				
LESION RATES				
OVERALL (a)	0/48 (0%)	0/45 (0%)	0/46 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.30	0/36.06	0/39.13	1/39.93
POLY-3 PERCENT (g)	0%	0%	0%	2.5%
TERMINAL (d)	0/34 (0%)	0/25 (0%)	0/31 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	439
STATISTICAL TESTS				
POLY 3	P=0.198	(e)	(e)	P=0.484
POLY 1.5	P=0.203	(e)	(e)	P=0.493
POLY 6	P=0.191	(e)	(e)	P=0.471
COCH-ARM / FISHERS	P=0.209	(e)	(e)	P=0.510
MAX-ISO-POLY-3	P=0.133	(e)	(e)	P=0.161

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Pituitary Gland: Pars Distalis
Angiectasis

LESION RATES

OVERALL (a)	7/50 (14%)	2/49 (4%)	6/50 (12%)	3/50 (6%)
POLY-3 RATE (b)	7/45.53	2/40.11	6/42.91	3/39.30
POLY-3 PERCENT (g)	15.4%	5%	14%	7.6%
TERMINAL (d)	6/36 (17%)	1/27 (4%)	4/34 (12%)	2/24 (8%)
FIRST INCIDENCE	668	586	586	688

STATISTICAL TESTS

POLY 3	P=0.271N	P=0.112N	P=0.546N	P=0.223N
POLY 1.5	P=0.251N	P=0.103N	P=0.543N	P=0.196N
POLY 6	P=0.299N	P=0.125N	P=0.540N	P=0.262N
COCH-ARM / FISHERS	P=0.223N	P=0.085N	P=0.500N	P=0.159N
MAX-ISO-POLY-3	P=0.227N	P=0.069N	P=0.427N	P=0.152N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Pituitary Gland: Pars Distalis				
Cyst				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/49 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/45.30	1/40.25	0/42.13	2/39.37
POLY-3 PERCENT (g)	0%	2.5%	0%	5.1%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	1/24 (4%)
FIRST INCIDENCE	---	526	---	670
STATISTICAL TESTS				
POLY 3	P=0.122	P=0.476	(e)	P=0.207
POLY 1.5	P=0.129	P=0.483	(e)	P=0.218
POLY 6	P=0.115	P=0.469	(e)	P=0.193
COCH-ARM / FISHERS	P=0.141	P=0.495	(e)	P=0.247
MAX-ISO-POLY-3	P=0.078	P=0.157	(e)	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Pituitary Gland: Pars Distalis
Hyperplasia

LESION RATES

OVERALL (a)	23/50 (46%)	19/49 (39%)	19/50 (38%)	20/50 (40%)
POLY-3 RATE (b)	23/46.17	19/42.26	19/43.66	20/43.77
POLY-3 PERCENT (g)	49.8%	45%	43.5%	45.7%
TERMINAL (d)	20/36 (56%)	13/27 (48%)	14/34 (41%)	7/24 (29%)
FIRST INCIDENCE	594	476	533	530

STATISTICAL TESTS

POLY 3	P=0.400N	P=0.403N	P=0.348N	P=0.428N
POLY 1.5	P=0.389N	P=0.374N	P=0.348N	P=0.406N
POLY 6	P=0.404N	P=0.439N	P=0.328N	P=0.448N
COCH-ARM / FISHERS	P=0.346N	P=0.300N	P=0.272N	P=0.343N
MAX-ISO-POLY-3	P=0.496N	P=0.327N	P=0.279N	P=0.349N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Skin: Epidermis
Cyst Epithelial Inclusion

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	1/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	2.5%	0%	0%
TERMINAL (d)	0/36 (0%)	1/27 (4%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	728 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.590N	P=0.473	(e)	(e)
POLY 1.5	P=0.585N	P=0.481	(e)	(e)
POLY 6	P=0.594N	P=0.464	(e)	(e)
COCH-ARM / FISHERS	P=0.567N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.414N	P=0.158	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Skin: Epidermis **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Spleen
Hematopoietic Cell Proliferation

LESION RATES

OVERALL (a)	42/50 (84%)	41/50 (82%)	42/50 (84%)	38/50 (76%)
POLY-3 RATE (b)	42/48.88	41/45.70	42/47.15	38/45.62
POLY-3 PERCENT (g)	85.9%	89.7%	89.1%	83.3%
TERMINAL (d)	32/36 (89%)	24/27 (89%)	30/34 (88%)	22/24 (92%)
FIRST INCIDENCE	397	476	275	461

STATISTICAL TESTS

POLY 3	P=0.351N	P=0.398	P=0.436	P=0.470N
POLY 1.5	P=0.275N	P=0.432	P=0.428	P=0.384N
POLY 6	P=0.473N	P=0.404	P=0.475	P=0.592N
COCH-ARM / FISHERS	P=0.186N	P=0.500N	P=0.607N	P=0.227N
MAX-ISO-POLY-3	P=0.376N	P=0.285	P=0.318	P=0.355N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Spleen **Hyperplasia**				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/45.30	0/39.63	1/42.13	0/39.15
POLY-3 PERCENT (g)	2.2%	0%	2.4%	0%
TERMINAL (d)	1/36 (3%)	0/27 (0%)	1/34 (3%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	---	728 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.412N	P=0.527N	P=0.744	P=0.529N
POLY 1.5	P=0.408N	P=0.519N	P=0.746	P=0.518N
POLY 6	P=0.418N	P=0.536N	P=0.744	P=0.544N
COCH-ARM / FISHERS	P=0.405N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.312N	P=0.191N	P=0.479	P=0.194N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Spleen **Necrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Spleen
Pigmentation Hemosiderin

LESION RATES

OVERALL (a)	44/50 (88%)	41/50 (82%)	40/50 (80%)	43/50 (86%)
POLY-3 RATE (b)	44/49.53	41/46.93	40/48.09	43/47.72
POLY-3 PERCENT (g)	88.8%	87.4%	83.2%	90.1%
TERMINAL (d)	32/36 (89%)	24/27 (89%)	27/34 (79%)	23/24 (96%)
FIRST INCIDENCE	397	322	119	439

STATISTICAL TESTS

POLY 3	P=0.494	P=0.538N	P=0.300N	P=0.553
POLY 1.5	P=0.530	P=0.506N	P=0.291N	P=0.595
POLY 6	P=0.439	P=0.585N	P=0.303N	P=0.484
COCH-ARM / FISHERS	P=0.500N	P=0.288N	P=0.207N	P=0.500N
MAX-ISO-POLY-3	P=0.466	P=0.410N	P=0.209N	P=0.415

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Stomach, Forestomach **Inflammation**				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/45.66	2/40.02	0/42.13	0/39.15
POLY-3 PERCENT (g)	2.2%	5%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	629	651	---	---
STATISTICAL TESTS				
POLY 3	P=0.212N	P=0.454	P=0.516N	P=0.531N
POLY 1.5	P=0.204N	P=0.467	P=0.513N	P=0.519N
POLY 6	P=0.221N	P=0.439	P=0.517N	P=0.547N
COCH-ARM / FISHERS	P=0.188N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.208N	P=0.256	P=0.178N	P=0.196N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Stomach, Forestomach **Necrosis**				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/45.76	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	2.2%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	594	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.283N	P=0.529N	P=0.516N	P=0.531N
POLY 1.5	P=0.291N	P=0.520N	P=0.514N	P=0.519N
POLY 6	P=0.269N	P=0.539N	P=0.518N	P=0.547N
COCH-ARM / FISHERS	P=0.306N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.180N	P=0.193N	P=0.179N	P=0.196N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Stomach, Forestomach: Epithelium
Hyperplasia

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	1/45.66	2/40.00	0/42.13	3/40.06
POLY-3 PERCENT (g)	2.2%	5%	0%	7.5%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	1/24 (4%)
FIRST INCIDENCE	629	651	---	541

STATISTICAL TESTS

POLY 3	P=0.214	P=0.454	P=0.516N	P=0.260
POLY 1.5	P=0.224	P=0.467	P=0.513N	P=0.277
POLY 6	P=0.202	P=0.439	P=0.517N	P=0.238
COCH-ARM / FISHERS	P=0.242	P=0.500	P=0.500N	P=0.309
MAX-ISO-POLY-3	P=0.168	P=0.256	P=0.178N	P=0.138

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Stomach, Glandular Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	1/39.76
POLY-3 PERCENT (g)	0%	0%	0%	2.5%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	530
STATISTICAL TESTS				
POLY 3	P=0.188	(e)	(e)	P=0.474
POLY 1.5	P=0.193	(e)	(e)	P=0.484
POLY 6	P=0.182	(e)	(e)	P=0.461
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.123	(e)	(e)	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Stomach, Glandular **Necrosis**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

		Females		
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Thymus **Atrophy**				
LESION RATES				
OVERALL (a)	47/48 (98%)	44/49 (90%)	49/50 (98%)	50/50 (100%)
POLY-3 RATE (b)	47/48.00	44/46.32	49/49.00	50/50.00
POLY-3 PERCENT (g)	97.9%	95%	100%	100%
TERMINAL (d)	33/34 (97%)	25/27 (93%)	34/34 (100%)	24/24 (100%)
FIRST INCIDENCE	397	322	119	61
STATISTICAL TESTS				
POLY 3	P=0.163	P=0.413N	P=0.496	P=0.492
POLY 1.5	P=0.153	P=0.364N	P=0.497	P=0.492
POLY 6	P=0.176	P=0.461N	P=0.496	P=0.492
COCH-ARM / FISHERS	P=0.126	P=0.107N	P=0.742	P=0.490
MAX-ISO-POLY-3	P=0.129	P=0.220N	P=0.156	P=0.156

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**
Thyroid Gland: C-Cell Hyperplasia				
LESION RATES				
OVERALL (a)	18/50 (36%)	18/50 (36%)	17/50 (34%)	19/50 (38%)
POLY-3 RATE (b)	18/45.67	18/40.41	17/43.67	19/41.30
POLY-3 PERCENT (g)	39.4%	44.5%	38.9%	46%
TERMINAL (d)	16/36 (44%)	14/27 (52%)	14/34 (41%)	13/24 (54%)
FIRST INCIDENCE	680	614	497	530
STATISTICAL TESTS				
POLY 3	P=0.344	P=0.395	P=0.568N	P=0.341
POLY 1.5	P=0.388	P=0.446	P=0.569N	P=0.398
POLY 6	P=0.290	P=0.336	P=0.556N	P=0.270
COCH-ARM / FISHERS	P=0.460	P=0.582N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.437	P=0.322	P=0.481N	P=0.274

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Urinary Bladder
Calculus Gross Observation

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	4.4%	0%	0%	0%
TERMINAL (d)	2/36 (6%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.102N	P=0.268N	P=0.254N	P=0.271N
POLY 1.5	P=0.106N	P=0.259N	P=0.252N	P=0.258N
POLY 6	P=0.097N	P=0.279N	P=0.253N	P=0.290N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.062N	P=0.105N	P=0.092N	P=0.107N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Urinary Bladder: Transitional Epithelium
Hyperplasia Adenomatous

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/45.30	0/39.63	0/42.13	0/39.15
POLY-3 PERCENT (g)	4.4%	0%	0%	0%
TERMINAL (d)	2/36 (6%)	0/27 (0%)	0/34 (0%)	0/24 (0%)
FIRST INCIDENCE	728 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.102N	P=0.268N	P=0.254N	P=0.271N
POLY 1.5	P=0.106N	P=0.259N	P=0.252N	P=0.258N
POLY 6	P=0.097N	P=0.279N	P=0.253N	P=0.290N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.062N	P=0.105N	P=0.092N	P=0.107N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 104 WEEKS

	Females			
DOSE	**0 MG/KG**	**1250 MG/KG**	**2500 MG/KG**	**5000 MG/KG**

Uterus: Endometrium
Hyperplasia Cystic

LESION RATES

OVERALL (a)	4/50 (8%)	5/50 (10%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	4/45.30	5/40.73	3/42.28	4/39.67
POLY-3 PERCENT (g)	8.8%	12.3%	7.1%	10.1%
TERMINAL (d)	4/36 (11%)	2/27 (7%)	2/34 (6%)	2/24 (8%)
FIRST INCIDENCE	728 (T)	618	691	640

STATISTICAL TESTS

POLY 3	P=0.565N	P=0.434	P=0.538N	P=0.569
POLY 1.5	P=0.541N	P=0.449	P=0.534N	P=0.597
POLY 6	P=0.533	P=0.418	P=0.536N	P=0.532
COCH-ARM / FISHERS	P=0.500N	P=0.500	P=0.500N	P=0.643N
MAX-ISO-POLY-3	P=0.608N	P=0.311	P=0.386N	P=0.425

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are theP-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
(e)	Value of Statistic cannot be computed.
(g)	Poly-3 adjusted lifetime tumor incidence.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***